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Abstract
Embryonic stem (ES) cells have a vast therapeutic potential given their
pluripotency, or the ability to differentiate into tissues from all three germ layers.
One of the ultimate goals of regenerative medicine is to isolate pluripotent stem
cells from patients. Nuclear reprogramming offers the possibility of creating
patient-specific cell lines, thus abrogating the need for immunosuppressants
following cell transplantation therapy. It was recently reported that the forced
expression of four transcription factors, Oct4, Sox2, c-Myc and Klf4 can induce a
pluripotent state in somatic cells, without the need for embryo destruction. The
work presented here aims to characterize reprogramming using defined factors
and provide insight into the mechanisms governing this process. It also seeks to
identify transient cues to induce reprogramming in somatic cells, alleviating the
need for virally transduced transcription factors that hinder its eventual clinical
use.
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Chapter 1
Introduction
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Adult, multicellular organisms are heterogeneous collections of specialized cell
types arising from a totipotent zygote. As that single cell zygote divides and
proceeds through development it undergoes irreversible differentiation events
that result in a progressive loss of potency. For example, embryonic stem (ES)
cells are pluripotent cells derived from the inner cell mass (ICM) of a blastocyst
stage embryo that are still able to self-renew indefinitely in vitro and differentiate
into tissue types from all three primordial germ layers: mesoderm, ectoderm and
endoderm. In contrast, cells isolated from the next stage of development, the
gastrula, are multipotent and only able to produce tissues from one of each germ
layer.  This hierarchical organization continues, terminating with post-mitotic
somatic cells that no longer have the ability to create other cells.  While it was
once believed that this loss of potency was due to the progressive removal of
genetic material, cloning experiments proved this idea to be false, showing that
the genetic information of an adult cell is equivalent to an embryonic cell. Rather
than genetic changes, developmental loss of potency is due to heritable
epigenetic events, which are chemical modifications of DNA regulating the
pattern of genes that are expressed and silenced.  This pattern of gene
expression offers a unique signaling “program” to a given cell type, and explains
the progressive loss of potency through development without a loss of genetic
material.
The absence of these acquired epigenetic marks in ES cells, and the associated
enhanced developmental potential, offers the possibility for their therapeutic use
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as donor sources for tissue transplants in patients with degenerative diseases.
Unfortunately, efforts to use ES cells in a therapeutic setting have many
obstacles, including the ethics of using embryonic material and immune rejection
of the transplanted material.   As an alternative solution, methods have been
developed by which epigenetic regulation in terminally differentiated somatic cells
can be removed, thus “reprogramming” these cells to a more primitive state. The
reprogramming of somatic cells in this way may provide a solution to the current
obstacles hampering application of ES cells in a therapeutic setting, as they do
not require embryo-derived material and could be made patient-specific, thus
alleviating immune rejection issues. Furthermore, these reprogrammed cells
provide a model for investigation of normal molecular regulation during early
development, without the ethical problems of ES material, or the contamination
and chromosomal abnormalities of currently available ES lines.
The work in this thesis focuses on the characterization and mechanics of somatic
cell reprogramming through the forced expression of the transcription factors
Oct4, Sox2, Klf4, and c-Myc. To put this work into proper context, I will discuss
the biology of ES cells and what is currently known about the maintenance of
pluripotency. I will also describe other methods to reprogram somatic cells,
including nuclear transfer and cell fusion.
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Embryonic stem cells
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of a
blastocyst stage embryo and are able to self-renew indefinitely in vitro while
maintaining pluripotency, or the ability to differentiate into all tissues of the
embryo proper. ES cells were initially isolated from mouse blastocysts, then later
generated from human blastocysts (Evans and Kaufman, 1981; Martin, 1981;
Thomson et al., 1998). The maintenance of pluripotency is regulated by the
interplay between transcription factors, signaling pathways and epigenetic
regulators, some of which are described below.
Genetic control of pluripotency
Oct4
Oct4, or Pou5f1, is a member of the POU family of transcription factors, which
binds to the octamer motif ATT(A/T)GCAT. Oct4 is important in early embryonic
development and is expressed in blastomeres, ICM, epiblast, and germ cells, as
well as in pluriptotent stem cells, including ES cells, embryonic germ (EG) cells,
and embryonic carcinoma (EC) cells (Okamoto et al., 1990; Rosner et al., 1990;
Scholer et al., 1990). Embryos null for Oct4 die around implantation and ES cells
cannot be derived from the blastocysts (Nichols et al., 1998). Oct4 has been
shown to act cooperatively with other genes in the nucleus, including Sox2
(Boiani and Scholer, 2005). Overexpression of Oct4 (by 50%) causes
differentiation into primitive endoderm and mesoderm in mouse ES cells (Niwa et
al., 2000). In vivo activation of Oct4 in epithelial tissues causes dysplasia and an
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expansion of progenitor cell populations (Hochedlinger et al., 2005), showing that
silencing of Oct4 in adult cell populations is crucial to their differentiation
capacities as well as showing that certain populations may be able to respond to
embryonic signaling.
Sox2
Sox2, a member of the SRY-related HMG-box family of transcription factors,
binds to the DNA sequence (A/T)(A/T)CAA(T/A)G, thereby regulating its target
genes. Sox2 is expressed in the ICM, epiblast and germ cells of the developing
embryo, as well as the extraembryonic ectoderm and neural stem cells and
neural progenitor cells. Embryos null for Sox2 die at implantation due to failure of
the epiblast (Avilion et al., 2003) and knock-out ES cells cannot be established.
There is evidence that SOX proteins cooperate with other proteins in order to
regulate gene expression, and Sox2 is known to heterodimerize with Oct4
(Kamachi et al., 2000).
Nanog
Nanog is a homeodomain transcription factor that plays a crucial role in early
embryonic development. Nanog is expressed in the developing morula, ICM and
epiblast as well as ES cells, EC cells and germ cells (Chambers et al., 2003;
Mitsui et al., 2003). Embryos null for Nanog die shortly after implantation at E5.5
due to a lack of epiblast tissue (Mitsui et al., 2003). Knockout ES cells can be
established but spontaneously differentiate into primitive endoderm.
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Overexpression of Nanog in ES cells induces independence from the cytokine
leukemia inhibitory factor (LIF) (see below). It has also been reported that hybrid
cells formed by the fusion of neural stem cells and ES cells overexpressing
Nanog reprogram with a higher efficiency, providing further evidence for Nanog’s
role in the maintenance of pluripotency (Silva et al., 2006).
Core transcriptional circuitry in ES cells
Given the importance of Oct4, Sox2 and Nanog in the maintenance of
pluripotency, numerous studies have analyzed their downstream targets to gain a
more detailed understanding of their molecular mechanisms of action. Genome-
wide location analysis for OCT4, NANOG, and SOX2 in both mouse and human
ES cells has demonstrated that these three genes form a core transcriptional
regulatory network that governs both pluripotency and the control of
differentiation in ES cells (Boyer et al., 2005; Loh et al., 2006). By binding to their
own promoters and the promoters of the other two factors, Oct4, Sox2 and
Nanog form an interconnected, autoregulatory loop (Figure 1). Coordinate
reinforcement of their own expression allows for maintenance of the pluripotent
cell “program” and provides evidence for the mechanism of self-renewal in ES
cells. Studies using an inducible Sox2-null ES line suggest that this is indeed the
case (Masui et al., 2007). ES cells that have lost Sox2 expression can be
rescued in two ways: 1) by the overexpression of Sox2, or 2) by the
overexpression of Oct4. This suggests that the function of Sox2 is, in part, to
regulate Oct4 expression.
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In addition to binding to each others’ promoters Oct4, Sox2 and Nanog share
numerous other target genes, co-occupying both active and inactive genes,
suggesting that transcriptional regulation is a concerted process requiring the
interaction of multiple proteins (Figure 1). Consistent with this hypothesis,
sequential immunoprecipitation experiments identified a protein-interaction
network for Nanog that consists of known regulators of pluripotency, including
Oct4 (Wang et al., 2006).
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Figure 1. Core transcriptional circuitry of ES cells. The Oct4, Sox2, and
Nanog transcription factors (blue circles) (i) participate in an interconnected
autoregulatory loop (bottom left), (ii) generally co-occupy the same sites in the
promoters of their target genes, and (iii) collectively target two sets of genes, one
that is actively expressed in ES cells and another that is silent in ES cells, but
remains poised for subsequent expression during differentiation (Boyer et al.,
2005). Polycomb Group proteins (PcG, green circle) co-occupy a set of silent
developmental regulators in ES cells that are expressed in differentiated cells in
a lineage-specific pattern. These genes show evidence of transcriptional initiation
by PNA Polymerase II (Pol2, gray oval), but are not productively transcribed in
ES cells.
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A surprising number of genes bound by Oct4, Sox2 and Nanog are
transcriptionally silent in pluripotent ES cells. Many of these inactive genes are
important transcription factors that are associated with lineage specification. This
suggests that Oct4, Sox2, and Nanog maintain pluripotency not only by activating
genes responsible for self-renewal, but also by directly repressing genes
associated with differentiation.
The genome-wide location analysis performed in the studies described above
utilized chromatin immunoprecipitation coupled to a microarray platform (ChIP-
chip for human cells) (Boyer et al., 2005) or sequencing analysis (ChIP-PET for
mouse cells) (Loh et al., 2006). While there were many overlapping gene targets
between these two analyses, including the promoters of Oct4, Sox2 and Nanog,
there were also significant differences between the studies. For example, some
genes were identified as target genes in only human ES cells, such as Hand1,
while others were recognized only in mouse ES cells, like Essrrb. It is known that
human and mouse ES cells respond differently to some signaling molecules (see
below). Therefore, these discrepancies may reflect those differences in the
pathways responsible for pluripotency between mouse and human ES cells
(Brons et al., 2007; Rossant, 2008; Tesar et al., 2007). Another possibility,
however, is that the different genomic platforms used in the studies created bias
in the identified target genes. Chromatin immunoprecipitation followed by direct
sequencing of bound DNA (ChIP-seq) could remove the bias associated with the
genomic platforms, but not address technical issues surrounding the
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immunoprecipitation, such as antibody specificity. Genetic manipulation of Oct4,
Sox2 and Nanog combined with expression analysis will begin to unravel the key
targets responsible for self-renewal (Loh et al., 2006).
Epigenetic control of pluripotency
ES cells display epigenetic hallmarks of plasticity, namely an “open” chromatin
(euchromatin) structure typified by acetylated histone modifications, while cells
undergoing differentiation exhibit characteristics of “closed” chromatin
(heterochromatin) such as decreased histone acetylation. In addition, specific
histone modifications, including methylation and acetylation, are associated with
euchromatin or heterochromatin. The dynamics of chromatin structure and the
heritability of chromatin marks play key roles in development and may therefore
have implications on reprogramming.
The developmental regulators bound by Oct4, Sox2 and Nanog are co-occupied
by Polycomb group (PcG) proteins, chromatin modifiers that are associated with
epigenetic silencing (Figure 1) (Bernstein et al., 2006; Boyer et al., 2006; Lee et
al., 2006). PcG proteins form two repressive complexes: PRC1 and PRC2. PRC2
catalyzes H3K27me3, a repressive mark that may allow PRC1 binding. Once
bound, PRC1 facilitates chromatin condensation and gene silencing. H3K27me3
was found associated with the developmental regulators, and loss of PRC2
components showed de-repression of the target genes, suggesting a functional
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link between PRC2 proteins and silencing of developmental regulators in ES
cells.
In addition to the H3K27me3 repressive mark, many developmental regulators in
ES cells also contain the active H3K4me3 mark, giving their promoters “bivalent”
domains (Bernstein et al., 2006). In addition to bivalent domains, the
developmental regulators bound by PcG undergo transcriptional initiation, but not
elongation (Guenther et al., 2007). This suggests that developmental regulators
are uniquely poised for expression in ES cells, supporting the ability of ES to
easily differentiate if given the proper cue(s). This also highlights the important
balance that must be maintained in ES cell cultures: to continually self-renew, yet
remain primed for differentiation.
Signaling pathways in pluripotency
The property of ES cell self-renewal is not entirely intrinsic, but also depends
upon extracellular signals. MEF feeder layers, as well as conditioned media,
confer the ability of ES cells to self-renew, suggesting they secrete factors
involved in the maintenance of pluripotency. Indeed, the cytokine LIF is
necessary for the maintenance of the undifferentiated state in mouse ES cells
and functions by activating the transcription factor Stat3 (Niwa et al., 1998; Smith
et al., 1988; Williams et al., 1988). Ying et al. showed that serum is dispensible in
mouse ES media if it is supplemented with BMP4 protein, showing a clear role of
BMP signaling in the self-renewing properties of ES cells (Ying et al., 2003).
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Inhibitor of differentiation (ID) proteins downstream of BMP4 suppress lineage
commitment in ES cells by blocking of FGF/ERK signaling (Silva and Smith,
2008), which is important for the initial stages of differentiation (Kunath et al.,
2007). Simultaneous inhibition of ERK and glycogen synthase kinase (GSK)-3
signaling in mouse ES cells renders them independent of LIF and BMP signaling,
highlighting the parallel signaling pathways involved in ES self-renewal (Ying et
al., 2008).
The Wnt signaling pathway promotes self-renewal in mouse and human ES cells
(Cai et al., 2007; Ogawa et al., 2006; Sato et al., 2004; Singla et al., 2006).
Canonical Wnt signaling leads to GSK-3 phosphorylation and sequestration,
allowing for β-catenin accumulation in the nucleus, where it associates with
Tcf/Lef family transcription factors and activation and/or repression of gene
expression (Figure 2). Tcf3 is the most abundant member of this transcription
factor family in ES cells and was recently shown to bind the same genomic
targets as Oct4, Sox2, and Nanog, indicating that Wnt signaling feeds into the
core transcriptional circuitry of pluripotency (Cole et al., 2008).
18
Figure 2. Canonical Wnt signaling pathway. Wnt ligand promotes the
association of Frizzled and LRP, leading to phosphorylation and inactivation of
GSK-3β (glycogen synthase linase 3β). β-catenin (B-cat) accumulates and
migrates to the nucleus where it associates with Tcf/Lef proteins, including Tcf3,
shown here, to target genes to regulate transcription.
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Interestingly, human ES cells have different signaling requirements than mouse.
For instance, unlike mouse ES cells, human ES cells do not require LIF/Stat3
signaling to maintain pluripotency and BMP signaling in human ES cells drives
differentiation rather than self-renewal (Yu and Thomson, 2008). Furthermore,
human ES cell pluripotency is maintained through FGF and TGFβ/Activin/Nodal
signaling (Yu and Thomson, 2008). These differences between human and
mouse ES cells could simply be due to differences in species-specific signaling
or could be due to a difference in the developmental stage of ES cell isolation. It
has been postulated that human ES cells more closely represent a primitive
streak stage of development, rather than a blastocyst stage (Brons et al., 2007;
Rossant, 2008; Tesar et al., 2007).
Laboratory use of ES cells
The isolation and use of ES cells as a laboratory tool has aided in the study of
developmental genetics and has led to numerous mouse models of human
disease. Animals in which a specific gene is deleted, or “knock-outs,” can be
engineered with the use of ES cells. A DNA construct is first generated with one
or more of a gene’s exons deleted, then is targeted to the corresponding
genomic locus in ES cells by homologous recombination. The engineered ES
cells are subsequently injected into blastocysts and because of their
pluripotency, can contribute to all somatic lineages and the germline in the
resulting chimeras. The chimeras are bred to wild-type mice to generate stable
transgenic lines that contain the deleted gene. One example of a knock-out
20
mouse that had important implications for understanding human disease
processes is the knock-out of the p53 tumor suppressor (Harvey et al., 1993;
Jacks et al., 1994). Although adult homozygous animals were obtained, they
were highly susceptible to tumor formation, providing key insight into cancer
biology. Targeted ES cells can also be engineered to carry a visible marker such
as GFP or lacZ downstream of a promoter to allow for lineage tracing within cell
populations. Targeted ES cells can be engineered to overexpress proteins,
resulting in transgenic animals with a more predictable expression pattern than
traditional transgenics (Beard et al., 2006).
The in vitro differentiation of ES cells into mesodermal, ectodermal and
endodermal cell types has been shown to recapitulate normal embryonic
development, making ES cells a unique in vitro system for studying differentiation
into specific tissue lineages. For instance, it has become possible to model the
process of gastrulation with ES cultures, providing a convenient in vitro system to
study the effects of genetic and epigenetic manipulation [reviewed in (Murry and
Keller, 2008).
Clinical use of ES cells
Beyond being used as a laboratory technology, ES cells offer the possibility for
therapeutic use as donor sources for tissue transplants in patients with
degenerative diseases. From ES cells one could potentially derive dopaminergic
neural cells to transplant into patients suffering from Parkinson’s disease,
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cardiomyocytes to treat heart failure patients, motor neurons or oligodendrocytes
to repair injured spinal cords, or any multitude of other cell types for a variety of
diseases (Murry and Keller, 2008). Despite their therapeutic potential, there are
restrictions to the current clinical use of ES cells. The first is a technical limitation.
We must be able to differentiate ES cells into the desired cell type at high
efficiency (or be able to purify out specific populations), transplant those cells and
have them incorporate physiologically into an organ. Care must be taken not to
introduce undifferentiated stem cells that are known to be tumorigenic. There is
continued progress regarding these issues and they may ultimately be overcome
with further understanding of disease processes and in vitro culturing systems.
Beyond these technical issues, other critical impediments to stem cell therapy
remain, including immune rejection of allogeneic transplanted cells and the
ethical use of human embryos to derive ES cells. “Reprogramming” a
differentiated cell to an ES cell would circumvent the latter two issues, providing
a patient-specific donor source for cell transplantation. There have been different
methods used to reprogram cells to a more embryonic state, including nuclear
transfer, cellular fusion, and the more recently identified transduction of defined
factors (Figure 3).
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Figure 3. Strategies to induce reprogramming of somatic cells. Three
methods for inducing reprogramming of somatic cells include nuclear transfer,
fusion, and forced expression of defined factors. Nuclear transfer involves the
injection of a somatic nucleus into an enucleated oocyte. If transferred to a
surrogate mother, it can give rise to an animal clone, but if explanted into culture,
it can give rise to genetically matched ES cells. Cell fusion of differentiated cells
with pluripotent ES cells gives rise to hybrids that have characteristics of
pluripotent cells. Viral transduction of four transcription factors, Oct4, Sox2, Klf4,
and c-Myc can induce a pluripotent state.
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Strategies for Reprogramming somatic cells
Nuclear transfer
Nuclear transfer involves the introduction of a nucleus from a donor cell into an
enucleated oocyte to generate a cloned animal. Briggs and King successfully
employed this method in the 1950s when they generated cloned tadpoles by
transferring nuclei of blastula stage embryos into enucleated Rana pipiens eggs
(King and Briggs, 1956). Their study further showed that while most nuclei from
early stage cells could form tadpoles when transferred into oocytes, it was
substantially more difficult to achieve with nuclei from later stages of
development, including gastrula and neurula. Gurdon and colleagues later
generated fertile, adult frogs when they transferred tadpole intestinal nuclei into
enucleated Xenopus laevis oocytes [reviewed in (Gurdon and Byrne, 2003)].
Interestingly, when the donor nuclei were from adult somatic cells they could only
generate tadpoles. Together these studies proved that cells at different
developmental stages are genetically equivalent. Although the genetic material in
a cell remains constant, epigenetic characteristics of DNA and chromatin
influence gene expression patterns and a cell’s developmental potency.
Nuclear transfer in mammals proved to be technically challenging, but was
successfully accomplished when Wilmut and colleagues cloned Dolly the sheep
from a differentiated mammary epithelial cell (Wilmut et al., 1997). Somatic cell
nuclear transfer (SCNT) was subsequently used to clone other mammalian
species, including mice (Wakayama et al., 1998), cows (Kato et al., 1998) and
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pigs (Onishi et al., 2000; Polejaeva et al., 2000). Consistent with the findings in
frogs, reproductive cloning in mice was easier with stem cells than with more
differentiated cells, though terminally differentiated murine lymphocytes and post-
mitotic olfactory neurons were successfully used as donor nuclei in nuclear
transfer experiments (Eggan et al., 2004; Hochedlinger and Jaenisch, 2002). In
order to obtain animals by nuclear transfer (NT) from terminally differentiated
cells, however, a “two-step” cloning process was employed where ES cells were
derived from NT embryos, followed by generation of mice from the NT ES cells.
Disease-specific NT ES cells were also used to treat an immune-deficient mouse
model through homologous recombination, providing proof-of-principle that
reprogrammed stem cells could be used therapeutically (Rideout et al., 2002).
The generation of animals via reproductive cloning is highly inefficient, with most
animals dying during gestation exhibiting a variety of maladies, including large
offspring syndrome (Chavatte-Palmer et al., 2000; Young et al., 1998) and
abnormal placentas (Hill et al., 2000; Wakayama and Yanagimachi, 1999). Faulty
epigenetic reprogramming is hypothesized as a main cause of the inefficiency in
nuclear transfer (Humpherys et al., 2002). Those animals that do survive suffer
severe abnormalities, including premature death and obesity (Hochedlinger and
Jaenisch, 2003; Yang et al., 2007). Interestingly, the derivation of ES cells from
NT embryos is much more efficient and there are indications that NT ES cells are
indistinguishable from embryo derived ES cells, which makes NT ES cells a good
source of patient-specific cell lines (Brambrink et al., 2006; Wakayama et al.,
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2006). Unfortunately, NT has not been successful to date with human cells. Even
if the technical obstacles of human NT were resolved, the ethical issues of
human oocyte usage and availability are further hindrances to its use as a
therapeutic cell source.
Reprogramming via cell fusion
Reprogramming of somatic cells by fusion was first demonstrated with mouse
thymocytes and EC cells (Miller and Ruddle, 1976) and later shown with mouse
ES cells (Tada et al., 2001). Fusion of human fibroblasts or hematopoietic cells
with hES cells also resulted in reprogrammed hybrids (Cowan et al., 2005; Yu et
al., 2006). While hybrids gain many hallmarks of reprogramming, including
reactivation of pluripotency genes in the somatic, differentiated genome, it is
unclear that the hybrid’s somatic genome is fully reprogrammed (Kimura et al.,
2004).
The molecular mechanisms governing reprogramming by fusion are poorly
understood. Both the cytoblast (Strelchenko et al., 2006) and the karyoblast (Do
and Scholer, 2004) of the ES cell have been implicated as the necessary cellular
compartment that contains the reprogramming “factors.” Of greater concern,
however, is the use of tetraploid cells for human cell-based therapy. The ES cell
genome will have to be removed to generate diploid cells before they can be
used therapeutically. While selective elimination of some ES cell chromosomes
was achieved using a chromosomal deletion cassette, the use of this technique
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to eliminate an entire genome poses significant risks of generating chromosomal
instability (Matsumura et al., 2007).
Transcription factor mediated reprogramming
A breakthrough in the field of reprogramming was achieved when Takahashi and
Yamanaka reported the generation of induced pluripotent stem (iPS) cells from
mouse embryonic and adult fibroblasts (Takahashi and Yamanaka, 2006)
(Figure 4). Based on the hypothesis that ES cells contain reprogramming
factors, 24 candidate factors were screened in combination for the ability to re-
activate Fbx15, a downstream target of Oct4 and Sox2 (Tokuzawa et al., 2003).
Retroviral-mediated transduction of four transcription factors (Oct4, Sox2, c-myc,
and Klf4) in fibroblasts, followed by selection for Fbx15 expression, generated
iPS cells that formed teratomas and contributed to chimeric embryos when
injected into blastocysts (Takahashi and Yamanaka, 2006). Fbx15-selected iPS
cells did not appear to be fully reprogrammed, however, as their gene expression
and DNA methylation patterns differed significantly from ES cells, showing little
endogenous expression of Oct4 and Nanog, among other genes. Furthermore,
Fbx15-selected iPS could not contribute to adult chimeras.
This pivotal study raised numerous questions, including the role of selection in
iPS cell generation, the role of viruses and the continued expression of the four
transcription factors, the epigenetic state of the iPS cells, the role for transcription
factor mediated reprogramming in human cells, and the mechanism of action of
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iPS formation. Subsequent studies, including those in this thesis, have begun to
address these questions. Although Fbx15 is a downstream target of Oct4 and
Sox2, it is not an essential gene for development or pluripotency (Tokuzawa et
al., 2003). When Oct4 or Nanog re-activation was used as a more stringent
selection criterion to generate iPS cells through retroviral-mediated four-factor
transduction, these iPS more closely resembled ES cells by numerous criteria,
including: (i) global gene expression and chromatin configuration, (ii) contribution
to adult, germline-competent chimeras as well as live, late-term embryos
generated by tetraploid complementation, (iii) re-expression of endogenous Oct4
and Nanog, and (iv) silencing of the Moloney-based viral transduced factors
(Chapter 2) (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007).
Some key questions regarding the use of selection markers in iPS cell generation
remain. Are the partially reprogrammed Fbx15-iPS cells intermediates because
of the timing of selection or because Fbx15 does not select for pluripotent cells?
It was subsequently determined that iPS cells can be isolated from culture
without selection by morphological criteria alone (Blelloch et al., 2007; Meissner
et al., 2007) suggesting that the Fbx15-iPS intermediates arose in the first
reprogramming report due to early selection and could have become fully
reprogrammed given enough time. However, the possibility does remain that
Fbx15 selection does maintain a different cell state in culture. Additional studies
are needed to sufficiently address this question.
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Several groups have more recently achieved reprogramming of other murine cell
types, including hepatocytes (Aoi et al., 2008) and progenitor B cells (Hanna et
al., 2008). Interestingly, reprogramming of mature B cells to iPS cells could only
be achieved with the addition of C-EBPα, a transcription factor known to facilitate
reprogramming of B cells into macrophages (Xie et al., 2004). This suggests that,
as in nuclear transfer, the efficiency of reprogramming of terminally differentiated
cells is lower than somatic stem cells, although further analysis needs to be done
to solidify this assertion.
Therapeutic use of iPS cells
iPS cells could provide patient-specific donor sources for therapeutic cell
transplantation, by substituting for pluripotent ES cells. iPS cells were used to
cure a mouse model of sickle cell anemia (Hanna et al., 2007) and iPS-derived
neurons transplanted into mouse model of Parkinson’s disease were able to
alleviate some of the symptoms associated with the disease (Wernig et al.,
2008b). These studies show great promise for iPS cells in patient-specific
transplantation therapy. The initial use of drug-dependent selection in the
generation of iPS cells hindered its applicability to human cells, as genetically
modified donor cells would be undesirable. The isolation of iPS cells based solely
on morphologic criteria proved these initial fears unfounded (Blelloch et al., 2007;
Meissner et al., 2007). Indeed, reprogramming of human fibroblasts and
keratinocytes has been reported (Park et al., 2008; Takahashi et al., 2007; Yu et
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al., 2007), both with the original four-factor combination (Oct4, Sox2, Klf4, and c-
Myc) and with Oct4, Sox2, Nanog, and Lin28 (Figure 4).
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Figure 4. Reprogramming using defined factors. Fibroblasts derived from
either murine or human sources are transduced with Oct4, Sox2, Klf4, and c-Myc
or Oct4, Sox2, Nanog, and Lin28. induced pluripotent stem (iPS) cells are
clonally derived following selection. These cells can give rise to derivatives of all
three germ layers as determined by teratoma formation and chimera contribution.
iPS cells have the potential to be differentiated into cell types that can be used as
potential therapies.
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Despite these breakthroughs in the field of reprogramming, there are key
concerns with using iPS cells therapeutically. One is the efficiency of
reprogramming, which is extremely low with reports ranging from roughly 0.05%
to 0.5% in mouse cells (Maherali et al., 2007; Okita et al., 2007; Wernig et al.,
2007) and 0.02% to 0.1% in human cells (Park et al., 2008; Takahashi et al.,
2007). The addition of known epigenetic modulators, including the DNA
methylation inhibitor 5-aza-cytidine and the HDAC inhibitor valproic acid (VPA),
were shown to increase the efficiency of reprogramming (Huangfu et al., 2008a;
Mikkelsen et al., 2008). Interestingly, VPA can substitute for viral transduction of
Klf4 and c-Myc in human cells, highlighting the importance of Oct4 and Sox2 in
the reprogramming process, as well as the possible differences between
reprogramming mouse and human cells (Huangfu et al., 2008b).
The main problem in using iPS cells therapeutically is the retroviral-mediated
transduction of transcription factors to achieve reprogramming, leading to
permanent transgene insertions in the iPS cell genome. It has been reported that
reactivation of the viral c-Myc transgene causes tumorigenesis in chimeras
generated from iPS cells (Okita et al., 2007). iPS cell formation was subsequently
achieved without c-Myc (Nakagawa et al., 2008; Wernig et al., 2008a), but the
efficiency of reprogramming was severely reduced. Furthermore, it remains
unclear whether the other transgenes, especially Klf4 (Foster et al., 2005), and
Oct4 (Hochedlinger et al., 2005), could cause tumors if reactivated.
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Recent studies have explored strategies to derive iPS cells with minimal or no
genetic manipulations. One study used a single virus carrying all four
reprogramming factors to infect and subsequently reprogram fibroblasts (Carey
et al., 2009). Another study was able to reprogram somatic cells by transiently
transfecting a single vector containing all four reprogramming factors (Okita et
al., 2008). A third group reported the use of non-integrating adenovirus to
overexpress the reprogramming factors (Stadtfeld et al., 2008b). While these
reports are a small step toward achieving reprogramming without genetic
manipulations, the efficiencies of reprogramming in these studies are a severe
hindrance to their continued use.
Small molecules and other transient cues may provide an alternative to viruses in
the future. Indeed, several studies, including two included in this thesis (Chapters
4 and 5), have found a role for small molecules in reprogramming. As previously
mentioned, the use of valproic acid and 5-aza-cytidine, has been shown to
increase the efficiency of reprogramming (Huangfu et al., 2008a; Mikkelsen et al.,
2008). BIX, a G9a histone methyltransferase inhibitor, was identified in a
chemical screen to increase the reprogramming efficiency of Oct4 and Klf4
infected neural precursor cells (Shi et al., 2008b). Oct4 expression is rapidly
downregulated upon differentiation and the Oct4 locus gains the
heterochromatin-associated marks H3K9me2 and H3K9me3, which is dependent
on the histone methyltransferase G9a (Feldman et al., 2006). Inhibition of G9a
could therefore promote Oct4 re-expression. BIX was subsequently used to
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replace Oct4 in Sox2, Klf4, and c-Myc infected neural precursor cells (Shi et al.,
2008b) and later used in combination with another chemical, BayK, a L-type
calcium channel agonist, to reprogram Oct4 and Klf4 infected fibroblasts (Shi et
al., 2008a).
Many of these initial chemical compounds were identified through a candidate
approach. The mechanism(s) by which these compounds act has been assumed
and not explored in detail. Knowledge of the mechanisms governing
reprogramming can inform the discovery of small molecules and vice versa.
High-throughput chemical screens offer the potential to isolate unique chemical
modulators that can provide key mechanistic insight into the process of
reprogramming, as well as functionally replace virally transduced transcription
factors.
Mechanisms of reprogramming to iPS cells
Initial studies exploring the mechanisms of reprogramming using defined factors
show that it is a gradual, sequential process, where the somatic cellular program
is converted to a pluripotent ES-like one (Chapter 3) (Brambrink et al., 2008;
Stadtfeld et al., 2008a). Our current knowledge of the biology of ES cells and
pluripotency may offer some comprehension of the mechanisms governing
reprogramming. Reprogramming is likely achieved by the reactivation of the
pluripotent autoregulatory loop, in part induced by Oct4 and Sox2
overexpression. Exogenous (viral) Oct4 and Sox2 can bind to the endogenous
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Oct4, Sox2 and Nanog loci, and once the feed-forward loop is active, the need
for the virally encoded transcription factors ceases (Figure 5). Oct4 and Sox2
were found to bind genes that encode known epigenetic modulators, such as
Smarcad1, Myst3, Jmjd1a and Jmjd2c (Loh et al., 2006; Loh et al., 2007),
suggesting a role for Oct4 and Sox2 in the epigenetic changes that occur during
the reprogramming process.
It was initially postulated that Klf4 and c-Myc might function together to transform
somatic cells and induce proliferation (Yamanaka, 2007). However, this may not
be the case. Recently, Klf4 was identified to bind to many of the same target
genes as Oct4, Sox2 and Nanog (Chen et al., 2008; Jiang et al., 2008; Kim et al.,
2008), suggesting that its role in reprogramming could be to cooperatively bind
with Sox2 and Oct4 to turn on the autoregulatory circuitry of pluripotency. The
difference in overlap of c-Myc target genes with those of Oct4, Sox2, and Klf4
have led to the hypothesis that the function of c-Myc in reprogramming is
separate from the other three factors (Chen et al., 2008; Kim et al., 2008). A
recent study supports this claim, providing evidence for c-Myc’s role in the initial
phases of reprogramming, including the downregulation of fibroblast-specific
genes (Sridharan et al., 2009). In addition, c-Myc might function to modify the
chromatin state of fibroblasts (Yamanaka, 2007) or promote DNA replication
(Dominguez-Sola et al., 2007), allowing for chromatin reorganization. Despite
some indication as to the mechanisms of reprogramming, these studies have
only begun to address how reprogramming of somatic cells is achieved.
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Figure 5. Model of the molecular circuitry during reprogramming. The
transduced factors likely bind to the endogenous pluripotency genes, including
Oct4, Sox2, and Nanog, gradually activating the autoregulatory loop of
pluripotency. Once the endogenous circuitry is active the virally transduced
factors are silenced by the de novo methyltransferases Dnmt3a and 3b.
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The isolation of iPS cells holds great promise for the field of regenerative biology,
but the current inability to achieve efficient, viral-free reprogramming presents a
significant hurdle to its clinical use. We also have a superficial understanding of
the mechanisms by which somatic cells are reprogrammed to iPS cells. A more
detailed knowledge of the mechanisms underlying the process of reprogramming
may allow the therapeutic use of iPS cells to become a reality.
The work in this thesis begins to address these shortcomings in our knowledge of
reprogramming. Chapter 2 builds on Takahashi and Yamanaka’s breakthrough
study, answering some of the questions that arose from this pivotal work.
Chapter 3 aims to provide some insight into the mechanism of reprogramming,
including defining the minimal expression requirements and temporal kinetics of
reprogramming. Chapter 4 analyzes the role of Wnt signaling in the
reprogramming of somatic cells. Chapter 5 details the replacement of viral Klf4
with a small molecule identified from a high-throughput chemical screen.
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Summary:
Nuclear transplantation can reprogram a somatic genome back into an
embryonic epigenetic state and the reprogrammed nucleus can create a cloned
animal or produce pluripotent embryonic stem cells. One potential use of the
nuclear cloning approach is the derivation of “customized” ES cells for patient
specific cell treatment but technical and ethical considerations impede the
therapeutic application of this technology. Reprogramming of fibroblasts to a
pluripotent state can be induced in vitro through ectopic expression of the four
transcription factors Oct4, Sox2, c-Myc and Klf4. Here we show that DNA
methylation, gene expression and chromatin state of such induced
reprogrammed cells are similar to those of ES cells. Importantly, the cells can
form viable chimeras, can contribute to the germ line and can generate live late-
term embryos when injected into tetraploid blastocysts. Our results show that the
biological potency and epigenetic state of in vitro reprogrammed iPS cells are
indistinguishable from that of ES cells.
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Epigenetic reprogramming of somatic cells into embryonic stem (ES) cells has
attracted much attention because of the potential for “customized” transplantation
therapy as cellular derivatives of reprogrammed cells will not be rejected by the
donor (Hochedlinger and Jaenisch, 2003; Yang et al., 2007). Thus far somatic
cell nuclear transfer and fusion of fibroblasts with ES cells have been shown to
promote the epigenetic reprogramming of the donor genome to an embryonic
state(Cowan et al., 2005; Hochedlinger and Jaenisch, 2006; Tada et al., 2001).
However, the therapeutic application of either approach has been hindered by
technical complications as well as ethical objections (Jaenisch, 2004). Recently,
a major breakthrough was reported by Takahashi and Yamanaka who
demonstrated that expression of the transcription factors Oct4, Sox2, c-Myc and
Klf4 induced fibroblasts to become pluripotent stem cells, designated as “induced
pluripotent stem (“iPS”) cells, though with a low efficiency(Takahashi and
Yamanaka, 2006). The iPS cells were isolated by selection for activation of
Fbx15, which is a downstream gene of Oct4. This landmark study left a number
of questions unresolved: (i) Although iPS cells were pluripotent they were not
identical to ES cells; for example, iPS cells injected into blastocysts generated
abnormal chimeric embryos that did not survive to term; (ii) gene expression
profiling revealed major differences between iPS cells and ES cells; (iii) because
the four transcription factors were transduced by constitutively expressed
retroviral vectors it was unclear why the cells could be induced to differentiate
and whether continuous vector expression was required for the maintenance of
the pluripotent state; (iv) the epigenetic state of the endogenous pluripotency
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genes Oct4 and Nanog was incompletely reprogrammed raising questions
about the stability of the pluripotent state.
Here we used the activation of the endogenous Oct4 or Nanog gene as a more
stringent selection strategy for the isolation for reprogrammed cells. We infected
fibroblasts with retroviral vectors transducing the four factors and selected for the
activation of the endogenous Oct4 or Nanog gene. Positive colonies resembled
ES cells and assumed an epigenetic state characteristic of ES cells. When
injected into blastocysts the reprogrammed cells generated viable chimeras and
contributed to the germ line. Our results establish that somatic cells can be
reprogrammed to a pluripotent state that is similar if not identical to that of normal
ES cells.
52
Selection of fibroblasts for Oct4 or Nanog activation
Using homologous recombination in ES cells we generated mouse embryonic
fibroblasts (MEFs) and tailtip fibroblasts (TTFs) that carried a neomycin
resistance marker inserted into either the endogenous Oct4 (Oct4-neo) or Nanog
locus (Nanog-neo) (Fig. 1a). These cultures were sensitive to G418, indicating
that the Oct4 and Nanog loci were as expected silenced in somatic cells. These
MEFs or TTFs were infected with Oct4, Sox2, c-Myc and Klf4 expressing
retroviral vectors and G418 was added to the cultures 3, 6 or 9 days later. The
number of drug resistant colonies increased substantially when analyzed at day
20 (Fig. 1i). Most colonies had a flat morphology (Fig.1 h right) and between 11
and 25% of the colonies were “ES-like” (Fig. 1h left) when selection was applied
early (Fig.1k), a number which increased at later time points. At day 20, ES-like
colonies were picked, dissociated and propagated in G418-containing media.
They gave rise to ES-like cell lines (designated as Oct4-iPS or Nanog-iPS cells,
respectively) which could be propagated without drug selection, displayed
homogenous Nanog, SSEA1 and AP expression (Fig.1b-g and Fig. S1 and S5)
and formed undifferentiated colonies when seeded at clonal density on gelatin-
coated dishes (see inset in Fig.1b). Four of five analyzed lines had a normal
karyotype (Table S1).
Although the timing and appearance of colonies was similar between the Oct4-
and Nanog-selection we noticed pronounced quantitative differences between
the two selection strategies: whereas Oct4-selected MEF cultures had 3- to 10-
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fold fewer colonies, the fraction of “ES-like colonies” was 2 to 3 fold higher than
in Nanog-selected cultures. Accordingly, ~4 times more Oct4-selected ES-like
colonies gave rise to stable and homogenous iPS cell lines (Fig.1k). This
suggests that although the Nanog locus was easier to activate a higher fraction
of the drug resistant colonies in Oct4-neo cultures were reprogrammed to a
pluripotent state. Therefore, the overall estimated efficiency of 0.05-.1% to
establish iPS cell lines from MEFs was similar between Oct4- and Nanog-
selection despite the larger number of total Nanog-neo resistant colonies
(Fig.1k). Next we investigated the time course of reprogramming by studying the
fraction of AP, SSEA1 and Nanog-positive cells in Oct4-selected MEF cultures.
Fourteen days after infection some cells had already initiated AP activity and
SSEA1 expression, but lacked detectable amounts of Nanog protein (Fig.1j)
whereas by day 20 AP and SSEA1 expression had increased and ~8% of the
cells were Nanog-positive. Thus, the four factor-induced reprogramming is a
gradual and slow process.
Expression and DNA methylation
To characterize the reprogrammed cells on a molecular level we used
quantitative RT-PCR (qRT-PCR) to measure expression of ES cell and fibroblast-
specific genes. Fig. 2a shows that in Oct4-iPS cells the total level of Nanog and
Oct4 was similar to that in ES cells but decreased upon differentiation to
embryoid bodies (EB). MEFs did not express either gene. Using specific primers
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for endogenous or total Sox2 transcripts showed that the vast majority of Sox2
transcripts originated from the endogenous locus rather than the viral vector (Fig.
2b). In contrast, HoxA9 and Zfpm2 were highly expressed in MEFs but at very
low levels in iPS or ES cells (Fig. 2c). Western analysis showed that multiple iPS
clones expressed Nanog and Oct4 protein at similar levels as ES cells (Fig. 2d).
Finally, we used microarray technology to compare gene expression patterns on
a global level. Fig. 2f shows that the iPS cells clustered with ES cells in contrast
to wild type or donor MEFs.
To investigate the DNA methylation level of the Oct4 and Nanog promoters we
performed bisulfite sequencing and COBRA analysis with DNA isolated from ES
cells, iPS cells and MEFs. As shown in Fig. 2g, both loci were demethylated in
ES and iPS cells and fully methylated in MEFs. To assess whether the
maintenance of genomic imprinting was compromised we assessed the
methylation status of the four imprinted genes H19, Peg1, Peg3 and Snrpn. As
shown in Fig. 2e, bands corresponding to an unmethylated (U) and methylated
(M) allele were detected for each gene in MEFs, iPS cells and tail tip fibroblasts.
In contrast, embryonic germ (EG) cells, which have erased all imprints(Labosky
et al., 1994), were unmethylated. Our results indicate that the epigenetic state of
the Oct4 and Nanog genes was reprogrammed from a transcriptionally repressed
(somatic) to an active (embryonic) state and that the pattern of somatic imprinting
was maintained in iPS cells. Also, the presence of imprints suggests a non-EG
cell origin of iPS cells.
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Chromatin modifications
Recently, downstream target genes of Oct4, Nanog and Sox2 have been defined
in ES cells by genome wide location analyses(Boyer et al., 2005; Loh et al.,
2006). These targets include many important developmental regulators, a
proportion of which are also bound and repressed by PcG complexes (Lee et al.,
2006),(Boyer et al., 2006). Notably, the chromatin at many of these non-
expressed target genes adopt a bivalent conformation in ES cells, carrying both
the “active” histone H3 lysine 4 (H3K4) methylation mark and the “repressive”
histone H3 lysine 27 (H3K27) methylation mark(Azuara et al., 2006; Bernstein et
al., 2006). In differentiated cells, those genes tend instead to carry either H3K4 or
H3K27 methylation depending on their expression state. We used chromatin
immunoprecipitation (ChIP) and real-time PCR to quantify H3K4 and H3K27
methylation for a set of genes reported to be bivalent in pluripotent ES
cells(Bernstein et al., 2006). Fig. 3a shows that the fibroblast specific genes
Zfpm2 and HoxA9 carried stronger H3K4 than H3K27 methylation in the donor
MEFs, whereas the silent genes Nkx2.2, Sox1, Lbx1h and Pax5 primarily carried
H3K27 methylation. In contrast, in the Oct4-iPS cells all of these genes showed
comparable enrichment for both histone modifications, similar to normal ES cells
(Fig. 3a). Identical results were obtained in Nanog-iPS clones selected from
Nanog-neo MEFs (Fig. S2). These data suggest that the chromatin configuration
of somatic cells is reset to one that is characteristic of ES cells.
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iPS cells tolerate genomic demethylation
Tolerance of genomic demethylation is a unique property of ES cells in contrast
to somatic cells that undergo rapid apoptosis upon loss of the DNA
methyltransferase Dnmt1(Jackson-Grusby et al., 2001; Li et al., 1992; Meissner
et al., 2005). We investigated whether iPS cells would be resistant to global
demethylation after Dnmt1 inhibition and would be able to re-establish global
methylation patterns after restoration of Dnmt1 activity. To this end, we utilized a
conditional lentiviral vector harboring a Dnmt1-targeting shRNA and a GFP
reporter gene (Fig. 3b(Ventura et al., 2004)). Infected iPS cells were plated at low
density and GFP-positive colonies were picked and expanded. Southern analysis
using HpaII digested genomic DNA showed that global demethylation of infected
iPS cells (Fig. 3c, lanes 6, 7) was similar to Dnmt1-/- ES (lane 2). In contrast,
uninfected iPS cells or MEFs (lanes 4, 5) displayed normal methylation levels.
Morphologically, the GFP-positive cells were indistinguishable from the parental
line or from uninfected sister subclones indicating that iPS cells tolerate global
DNA demethylation. In a second step, the Dnmt1 shRNA was excised through
Cre-mediated recombination and GFP negative clones were picked (Fig. 3d).
The cells had excised the shRNA vector (Fig. 3e) and normal DNA methylation
levels were restored (Fig. 3c, lane 8) as has been reported previously for ES
cells(Holm et al., 2005). These observations imply that the de novo
methyltransferases Dnmt3a/b were reactivated in iPS cells(Okano et al., 1999)
leading to restoration of global methylation levels. As expected(Holm et al.,
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2005), the imprinted genes Snrpn and Peg3 were unmethylated and resistant to
remethylation (Fig. 3f).
Maintenance of the pluripotent state
Southern analysis indicated that the Oct4-neo iPS clone 18 carried 4-6 copies of
the Oct4, c-Myc and Klf4 and only 1 copy of Sox2 retroviral vectors (Fig. 4a).
Because these four factors were under the control of the constitutively expressed
retroviral LTR it was unclear in the previous study why iPS cells could be induced
to differentiate(Takahashi and Yamanaka, 2006). To address this question, we
designed primers specific for the 4 viral encoded factor transcripts and compared
expression levels by qRT-PCR in MEFs 2 days after infection, in iPS cells, in
embryoid bodies (EB) derived from iPS cells and in demethylated and
remethylated iPS cells (Fig. 4b). Although the MEFs represented a heterogenous
population composed of uninfected and infected cells, virally encoded RNA levels
of Oct4, Sox2, and Klf4 RNA were 5 fold and of c-Myc more than 10 fold lower in
iPS cells than in the infected MEFs suggesting silencing of the viral LTR by de
novo methylation upon reprogramming. Accordingly, the total Sox2 and Oct4
RNA levels in iPS cells were similar to that in wt ES cells and, moreover, the
Sox2 transcripts in iPS cells were mostly if not exclusively transcribed from the
endogenous gene (compare Fig. 2b). Upon differentiation to EBs, both viral and
endogenous transcripts were down regulated. All viral Sox2, Oct4 and Klf4
transcripts were about 2-fold upregulated in Dnmt1 knock down iPS cells and
again downregulated upon restoration of Dnmt1 activity. This is consistent with
58
previous data that Moloney virus is efficiently de novo methylated and silenced
in embryonic but not in somatic cells (Jähner et al., 1982; Stewart et al., 1982).
Transcript levels of c-Myc were about 20 fold lower in iPS cells than in infected
MEFs and did not change upon differentiation or demethylation.
To follow the kinetics of vector inactivation during the reprogramming process we
isolated RNA from drug-resistant cell populations at different times after infection.
Fig. 4c shows that the viral vector encoded transcripts were gradually silenced
during the transition from MEFs to iPS cells with a time course that corresponded
to the gradual appearance of pluripotency markers (compare Fig. 1j). Finally, to
directly visualize Oct4 and Nanog expression during differentiation we injected
Oct4-iPS cells into SCID mice to induce teratoma formation (Fig. 4d).
Immunostaining revealed that Oct4 and Nanog were expressed in the centrally
located undifferentiated cells but were silenced in the differentiated parts of the
teratoma (Fig. 4e, f). Our results suggest that the retroviral vectors are subject to
gradual silencing by de novo methylation during the reprogramming process.
The maintenance of the pluripotent state and induction of differentiation strictly
depends on the expression and normal regulation of the endogenous Oct4 and
Nanog genes.
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Developmental potency
We determined the developmental potential of iPS cells by teratoma and chimera
formation. Histological and immunohistochemical analysis of Oct4- or Nanog-iPS
cell induced teratomas revealed that the cells had differentiated into cell types
representing all three embryonic germ layers (Fig. S3 and S4). To more
stringently assess their developmental potential various iPS cell-lines were
injected into diploid (2N) or tetraploid (4N) blastocysts. Following injection into 2N
blastocysts both Nanog- and Oct4-iPS clones derived from MEFs (Fig. 5a) or
from tail tip fibroblasts (Fig. 5b,c) as well as iPS cells that had been subjected to
a consecutive cycle of demethylation and remethylation (compare Fig. 3b, c)
efficiently generated viable high-contribution chimeras (summarized in Table 1).
To test for germ line transmission chimeras derived from two different iPS lines
(Oct4-iPS O9 and O16) were mated with normal females, blastocysts were
isolated and genotyped by 3 different PCR reactions for the presence of the
multiple viral Oct4 and c-myc genes and for the single copy GFP-neo sequences
inserted into the Oct4 locus of the donor cell (Fig. 1a). Fig. 5f shows that 9 of 16
embryos from 2 chimeras were positive for the viral copies. As expected, only
half of the viral positive blastocysts contained the GFP-neo sequences (5/9
embryos, left panel). When E.10 embryos derived from an Oct4-iPS line O16
chimera were genotyped 3/8 tested embryos were transgenic (right panel).
Finally, we injected iPS cells into 4N blastocysts as this represents the most
rigorous test for developmental potency because the resulting embryos are
composed only of the injected donor cells (“all ES embryo”). Fig. 5d,e show that
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both Oct4- and Nanog-iPS cells could generate mid- and late-gestation “all iPS
embryos” (summarized in Table 1). These findings indicate that iPS cells can
contribute to all lineages of the embryo and thus have a similar developmental
potential as ES cells.
Discussion
The results presented in this paper demonstrate that the four transcription factors
Oct4, Sox2, c-Myc and Klf4 can induce epigenetic reprogramming of a somatic
genome to an embryonic pluripotent state. . In contrast to selection for Fbx15
activation(Takahashi and Yamanaka, 2006), fibroblasts that had reactivated the
endogenous Oct4 (Oct4-neo) or Nanog (Nanog-neo) loci grew feeder
independently, expressed normal Oct4, Nanog and Sox2 RNA and protein levels,
were epigenetically identical to ES cells by a number of criteria and were able to
generate viable chimeras, contribute to the germ line and generate viable late-
gestation embryos after injection into tetraploid blastocysts. Transduction of the 4
factors generated significantly more drug resistant cells from Nanog-neo than
from Oct4-neo fibroblasts but a higher fraction of Oct4-selected cells had all
characteristics of pluripotent ES cells suggesting that Nanog activation is a less
stringent criterion for pluripotency than Oct4 activation.
Our data suggest that the pluripotent state of Oct4- and Nanog-iPS cells is
induced by the virally transduced factors but is largely maintained by the activity
of the endogenous pluripotency factors including Oct4, Nanog and Sox2 because
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the viral controlled transcripts, though expressed highly in MEFs, become
mostly silenced in iPS cells. The total levels of Oct4, Nanog and Sox2 were
similar in iPS and wt ES cells. Consistent with the conclusion that the pluripotent
state is maintained by the endogenous pluripotency genes is that the Oct4 and
the Nanog genes became hypomethylated in iPS as in ES, and that the bivalent
histone modifications of developmental regulators were re-established. Also, iPS
cells were resistant to global demethylation induced by inactivation of Dnmt1
similar to ES cells and in contrast to somatic cells. Re-expression of Dnmt1 in the
hypomethylated ES cells resulted in global remethylation indicating that the iPS
cells had also reactivated the de novo methyltransferases Dnmt3a/b. All these
observations are consistent with the conclusion that the iPS cells have gained an
epigenetic state that is similar to that of normal ES cells. This conclusion is
further supported by the recent observation that female iPS cells, similar to ES
cells, reactivate the somatically silenced X chromosome (Maherali et al., 2007).
Expression of the four factors proved to be a robust method to induce
reprogramming of somatic cells to a pluripotent state. However, the use of
retrovirus-transduced oncogenes represents a serious barrier to the eventual use
of reprogrammed cells for therapeutic application. Much work is needed to
understand the molecular pathways of reprogramming and to eventually find
small molecules that could achieve reprogramming without gene transfer of
potentially harmful genes.
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Methods summary
Cell culture, gene targeting and viral infections. ES and iPS cells were
cultivated on irradiated MEFs. Using homologous recombination we generated
ES cells carrying an IRES-GfpNeo fusion cassette downstream of Oct4 exon 5
(Fig. 1a). The Nanog gene was targeted as described (Mitsui et al., 2003).
Transgenic MEFs were isolated and selected from E13.5 chimeric embryos
following blastocyst injection of Oct4-IRES-GfpNeo or Nanog-neo targeted ES
cells. MEFs were infected overnight with the Moloney-based retroviral vector
pLIB (Clontech) containing the murine cDNAs of Oct4, Sox2, Klf4 and c-Myc.
Southern blot, methylation and chromatin analysis. To assess the levels of
DNA methylation, genomic DNA was digested with HpaII, and hybridized to a
probe for the minor satellite repeats (Chapman et al., 1984), or with an IAP-probe
(Walsh et al., 1998). Bisulfite treatment was performed with the Qiagen EpiTect
Kit. For the methylation status of Oct4 and Nanog promoters bisulfite sequencing
analysis was performed as described previously (Blelloch et al., 2006). For
imprinted genes, a COBRA assay was performed. PCR primers and conditions
were as described previously (Lucifero et al., 2002). The status of bivalent
domains was determined by chromatin immunopreciptation followed by
quantitative PCR analysis as described before (Boyer et al., 2006)
Expression analysis. Total RNA was reverse transcribed and quantified using
QuantTtect SYBR green RT-PCR Kit (Qiagen) on a 7000 ABI detection system.
Western blot and immunofluorescence analysis was performed as described
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(Hochedlinger et al., 2005; Wernig et al., 2004). Microarray targets from 2µg
total RNA were synthesized and labeled using the Low RNA Input Linear Amp Kit
(Agilent) and hybridized to Agilent whole mouse genome oligo arrays (G4122F)
and analyzed as previously described (Brambrink et al., 2006).
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Full Methods
Cell culture, MEF isolation, gene targeting and viral infections. ES and iPS
cells were cultivated on irradiated MEFs in DME containing 15% fetal calf serum,
Leukemia Inhibiting Factor (LIF), penicillin/streptomycin, L-glutamine, and non-
essential amino acids. All cells were depleted of feeder cells for two passages on
0.2% gelatin before RNA, DNA or protein isolation. Transgenic MEFs were
isolated and selected in 2µg/ml puromycin (Sigma) from E13.5 chimeric embryos
following blastocyst injection of Oct4-inducible KH2 ES cells (Hochedlinger et al.,
2005) which had been previously targeted with either Oct4-IRES-GfpNeo or
Nanog-neo constructs (Fig. 1a, (Mitsui et al., 2003)). Using homologous
recombination in ES cells, an IRES-GfpNeo fusion cassette was inserted into the
BclI site downstream of Oct4 exon 5. Correctly targeted ES cell clones were
screened by Southern analysis of NcoI digested DNA using a 5’ external probe.
The murine cDNAs for Oct4, Sox2, Klf4 and c-Myc were PCR amplified from ES
cell cDNA, sequence verified and cloned into the Moloney-based retroviral vector
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pLIB (Clontech). 2x105 MEFs or TTFs at passage 2-4 were infected overnight
with pooled viral supernatant generated by transfection of 4x106 HEK293T cells
(Fugene, Roche) with 10µg of viral vectors and the packaging plasmid pCL-Eco
in a 10 cm dish (Naviaux et al., 1996).
Blastocyst injection
Diploid or tetraploid blastocysts (94-98 hours post HCG injection) were placed in
a drop of DMEM with 15% FCS under mineral oil. A flat tip microinjection pipette
with an internal diameter of 12–15 mm was used for iPS cell injection (utilizing a
Piezo micromanipulator (Eggan et al., 2001)). A controlled number of cells were
injected into the blastocyst cavity. After injection, blastocysts were returned to
KSOM media and placed at 37°C until transferred to recipient females.
Recipient females and caesarean sections
Ten to fifteen injected blastocysts were transferred to each uterine horn of 2.5
days post coitum pseudo pregnant B6D2F1 females. To recover full-term pups
recipient mothers were sacrificed at 19.5 days postcoitum. Surviving pups were
fostered to lactating BALB/c mothers.
Southern blot, methylation and chromatin analysis.
To assess the levels of DNA methylation, genomic DNA was digested with HpaII,
and hybridized to pMR150 as a probe for the minor satellite repeats (Chapman et
al., 1984), or with an IAP-probe (Walsh et al., 1998). Bisulfite treatment was
performed with the Qiagen EpiTect Kit. For the methylation status of Oct4 and
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Nanog promoters bisulfite sequencing analysis was performed as described
previously (Blelloch et al., 2006). 10-20 clones of each sample were sequenced
in both directions. For imprinted genes, a COBRA assay was performed. PCR
primers and conditions were as described previously (Lucifero et al., 2002). PCR
products after bisulfite treatment and gel purification were digested with BstUI
(CGCG; H19, Peg3 and Snrpn) or HpyCH4 IV (ACGT; Peg1) and resolved on a
2% agarose gel. Unmethylated CpGs in the recognition sequence will be
converted to T and not cut. The status of bivalent domains was determined by
chromatin immunopreciptation followed by quantitative PCR analysis as
described before (Boyer et al., 2006)
Expression analysis.
50 ng of total RNA isolated using TRIzol reagent (Invitrogen) was reverse
transcribed and quantified using QuantTtect SYBR green RT-PCR Kit (Qiagen)
on a 7000 ABI detection system. Western blot and immunofluorescence analysis
was performed as described (Hochedlinger et al., 2005; Wernig et al., 2004).
Primary antibodies included Oct4 (monoclonal mouse, Santa Cruz), Nanog
(polyclonal rabbit, Bethyl), actin (monoclonal mouse, Abcam), SSEA1
(monoclonal mouse, Developmental Studies Hybridoma Bank). Fluorophor-
labeled secondary antibodies were purchased from Jackson Immunoresearch.
Microarray targets from 2µg total RNA were synthesized and labeled using the
Low RNA Input Linear Amp Kit (Agilent) and hybridized to Agilent whole mouse
genome oligo arrays (G4122F). Arrays were scanned on an Agilent G2565B
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scanner and signal intensities were calculated in Agilent FE software. Datasets
were normalized using a R script (available at http://www.ebi.ac.uk/arrayexpress)
and clustered as previously described (Brambrink et al., 2006).
Viral integrations
Genomic DNA was digested with SpeI overnight. Followed by electrophoresis
and transfer, the blots were hybridized to the respective radioactively labeled
cDNAs of the four transcription factors.
Genotyping
Blastocysts were lysed for 4 hours in 10µl 50mM Tris pH8.8 containing 1mM
EDTA and 0.5% Tween20 and 200µg/ml Proteinase K. After heat inactivation for
15 min, PCR was performed with the following conditions: 95°C 30" (1 cycle);
95°C 10", 60°C 15", 72°C 15" (40 cycles); 72°C 5'.
Primer sequences for genotyping
GFP-F TCCATGGCCAACACTAGTCA
GFP-R TCCCAGAATGTTGCCATCTT
pLIB-FW1 CCCCCTTGAACCTCCTCGTTCGAC
Oct4R GAGGTTCCCTCTGAGTTGCTTT
MycR CGAATTTCTTCCAGATATCCTCAC
Primer sequences for viral-specific qRT-PCR
rtKlf4_virusF1 TCTCTAGGCGCCGGAATTC
rtKlf4_virusR1 CCATGTCAGACTCGCCAGGT
rtMyc_virusF1 CTTCTCTAGGCGCCGGAATT
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rtMyc_virusR1 TGGTGAAGTTCACGTTGAGGG
rtOct4_virusF1 TACACCCTAAGCCTCCGCCT
rtOct4_virusR1 ATTCCGGCGCCTAGAGAAG
rtSox2_virusF1 TACACCCTAAGCCTCCGCCT
rtSox2_virusR1 ATTCCGGCGCCTAGAGAAG
DNMT1 hairpin target sequence DZ
GGAAAGAGATGGCTTAACA
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Table 1
2N injections 4N injections
cell line injectedblast.
live
chimeras
chimerism
(%)
Germ
line
injected
blast.
dead
embryos
(arrested)
live
embryos
(analyzed)
O6 - - - - 13 0 2 (E12.5)
O9 30 5 30-70 yes 90 3 (E11-13.5) 12 (E10-12.5)
O16 15 3 10-30 yes - - -
O18 95 8 5-50 no 134 7 (E9-11.5) 4* (E10-12.5)
O3-2 - - - - 25 2 (E8,11.5) 0
O4-16 - - - - 35 4 (E11-13.5) 3 (E14.5)
N7 30 1 30 - - - -
N8 90 14 5-50 no 118 9 (E9-11.5) 1* (E12.5)
N14 30 5 5-20 - 46 2 (E8,11.5) 1 (E12.5)
TT-O25 50 2 30† - 39 3 (E9.5) 0
O18 rem/3.1 25 1 30 - - - -
*developmentally retarded or abnormal; † based on GFP fluorescence
Summery of 2N and 4N injections. The extent of chimerism was estimated
based on coat color or EGFP expression (); * developmentally retarded. – not
determined. 4N injected blastocysts were analyzed between embryonic day
E10.5 and E14.5. Analyzed = day of embryonic development analyzed; arrested
= estimated stage of development of dead embryos.
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Figure legends
Fig. 1
Generation of Oct4- and Nanog-selected iPS cells. a) Targeting strategy to
generate an Oct4 IRES-GfpNeo allele. The resulting GfpNeo fusion protein has
sufficient neomycin resistance activity in ES cells, GFP fluorescence however is
not visible.  b) Phasecontrast micrograph of Oct4-iPS cells (clone 18) grown on
irradiated MEFs. Inset: ES cell-like colony 5 days after seeding in clonal density
without feeder cells. iPS clone 18 cells exhibited strong alkaline phosphatase
activity (c) and were homogenously labeled with antibodies against SSEA1 (d,e)
and Nanog (f,g). h) One example of an ES-like colony 16 days after infection
(left). The majority of G418-resistant colonies, however, consisted of flat non-ES-
like cells (right). i) Gradual activation of the Nanog and Oct4-neo alleles. Shown
are the total colony numbers of one experiment at day 20 after infection starting
neo-selection at day 3, 6, and 9. j) Fraction of total selected cells expressing AP,
SSEA1 and Nanog 0, 14, and 20 days after infection (counted were more than 10
visual fields containing n> 1000 total cells for every time point; s.d.). k) Estimated
reprogramming efficiency of Oct4- and Nanog-selection (n=3 different
experiments; +/- s.e.m.). Indicated are the total number of drug-resistant colonies
per 100.000 plated MEF cells 20 days after infection; the fraction of “ES-like”
colonies per total number of colonies; the fraction of iPS cell lines which could be
established from picked “ES-like” colonies as defined by homogenous AP,
SSEA1 and Nanog expression. After determining the fraction of Sox2 (83.4%),
Oct4 (53.2%) and c-Myc (46.3%)-infected MEFs 2 days after infection by
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immunofluorescence and assuming 50% were infected by Klf4 viruses we
estimated the overall reprogramming efficiency as the ratio of quadruple infected
cells and the extrapolated total number of iPS cell lines that could be established
with G418 selection starting at day 6 post infection.
Fig. 2
Expression and promoter methylation analysis of iPS cells. a-c) qRT-PCR
analysis (n = 3 independent PCR reactions; s.d.) of Oct4-iPS clone 18, subclone
18.1, 2 week-old embryoid bodies (EBs) derived from clone 18, V6.5 ES cells
and Oct4-neo MEFs shows similar Nanog (red bars) and total Oct4 (blue bars)
levels as in ES cells (a); slightly lower total Sox2 levels (filled red bars) most of
which was due to expression of endogenous Sox2 transcripts (open red bars, b);
strong downregulation of HoxA9 (red) and Zfpm2 (blue) transcripts in iPS cells
(c). Transcript levels were normalized to GAPDH expression with expression
levels in ES cells (a,b) and MEFs (c) set as “1”. d) Western blot analysis for Oct4
and Nanog expression of different Oct4-iPS clones (6,9,10,16,18) and a GFP
labeled subclone of clone 18 (18.1). e) COBRA methylation analysis(Eads and
Laird, 2002) of imprinted genes H19 (maternally expressed), Peg1 (paternally
expressed), Peg3 (paternally expressed) and Snrpn (paternally expressed).
Upper band = unmethylated (U); lower bands = methylated (M). f) Unsupervised
hierarchical clustering of averaged global transcriptional profiles obtained from
Oct4-neo iPS clone 18, Nanog-neo iPS clone 8, genetically matched ES cells
(V6.5;129/B6), Oct4-neo MEFs (O), Nanog-neo MEFs (N) and wildtype 129/B6
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F1 MEFs (wt). g) Analysis of the methylation state of the Oct4 and Nanog
promoter using bisulfite sequencing. Open circles indicate unmethylated and
filled circles methylated CpG dinucleotides. Shown are 8 representative
sequenced clones from ES cells (V6.5), Oct4-neo MEFs and Oct4-neo iPS clone
18.
Fig. 3
Reprogrammed MEFs acquire an ES cell-like epigenetic state. a) Real-time
PCR after chromatin immunoprecipitation using antibodies against tri-methylated
histone H3K4 and H3K27. Shown are the log2 enrichments for several previously
reported ‘bivalent’ loci in ES cells (n=3 experiments; s.d.). Zfpm2 and HoxA9
show enrichment for the active (H3K4) mark in MEFs and are expressed (Fig. 1c
and microarray data) whereas the other tested genes remain silent (microarray
data). All loci tested in iPS clone O18 show enrichment for both H3K4 and
H3K27 tri-methylation (‘bivalent’), as seen in ES cells (V6.5, 129/B6F1). See
Supplemental Fig. S2 for H3K4 and H3K27 tri-methylation analysis of a subclone
(clone O18.1) and Nanog-neo iPS clone N8. b) Experimental design to de- and
remethylate genomic DNA. Clone O18 was infected with the Dnmt1 hairpin
containing lentiviral vector pSicoR-GFP. The shRNA and GFP marker in the
pSicoR vector are flanked by LoxP sites(Ventura et al., 2004)). Green colonies
were expanded and passaged 4 times. Tat-Cre protein transduction was used to
remove the shRNA(Peitz et al., 2002). c) Southern blot analysis of the minor
satellite repeats using a methylation sensitive restriction enzyme (HpaII) and its
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methyl insensitive isoschizomer (MspI) as a control. Loss of methylation in two
different clones (lanes 6 and 7) is comparable to Dnmt1 knockout ES cells (lane
2). After Cre-mediated recombination complete remethylation (lane 8) of the
repeats is observed within 4 passages. d) Successful loop out after tat-Cre
treatment was identified by disappearance of EGFP fluorescence (arrow) and
verified by PCR analysis (e). f) COBRA assay of the imprinted genes Peg3 and
Snrpn and a random intergenic region close to the Otx2 locus (Interg.)
demonstrating the expected resistance to de novo methylation of imprinted
genes in contrast to non-imprinted intergenic sequences. U=unmethylated band,
M=methylated bands.
Fig. 4
Efficient silencing of retroviral transcripts in induced pluripotent cells. a)
Southern blot analysis of proviral integrations in iPS clone O18 (left lanes) for the
four retroviral vectors. Uninfected ES cells (right lanes) show only one or two
bands corresponding to the endogenous gene (marked by *). b) Quantitative RT-
PCR using primers specifically detecting the four viral transcripts. Shown are
Oct4-neo iPS clone 18 and a GFP labeled subclone, Oct4-neo MEFs, 2-week old
EB’s generated from clone 18, two demethylated clones (18 dem/1 and 18
dem/3), a remethylated clone (18 rem/3.1) and Oct4-neo MEFs 2 days after
infection with all 4 viruses but not selected with G418 (n = 3 independent
experiments; s.d.). c) Viral transcript levels at various time points in cell
populations after infection and Oct4-selection and in the two Oct4-iPS cell-lines
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O1.3 and O9 (n = 3 independent experiments; s.d.). d-f) Paraffin sections of a
teratoma 26 days after subcutaneous injection of Oct4-iPS clone 18 cells into
SCID mice. Nanog (e) and Oct4 (f) expression was confined to undifferentiated
cell types based on immunohistochemical analysis.
Fig. 5
Developmental pluripotency of reprogrammed fibroblasts. a) A 6 week old
chimeric animal. Agouti coloured hairs originated from Oct4-iPS cell line O18.1.
b) Two live pups after 2N blastocyst injection one of which shows high
contribution (c) of the tailtip fibroblast-derived Oct4-iPS cell line TT-O25, which
had been GFP labeled with a lentiviral Ubiquitin-EGFP vector. d) “all iPS cell
embryos” were generated by injection of iPS cells into 4N blastocysts(Eggan et
al., 2001). Live E12.5 embryos generated from Oct4-iPS line O6 (left embryo),
from Nanog-iPS line N14 (middle embryo) and from V.6.5 ES cells (right
embryo). e) A normally developed E14.5 embryo was derived from Oct4-iPS cell
line O4-16 after tetraploid complementation which was isolated by screening
MEFs for activation of GFP inserted into the Oct4 locus. f) Germline contribution
of the Oct4-iPS clones O9 and O16. Genotyping of blastocysts from females
mated with 3 chimeric males demonstrated the presence of Oct4- and c-Myc
virus integrations and the Oct4-IRES-GfpNeo allele (left panel). Because of the
multiple integrations (Fig. 4a) all embryos with iPS cell contribution are expected
to be positive for proviral sequences in this assay. In contrast the single copy
Oct4-IRESGfpNeo allele segregated into only 5 of the 9 virus positive embryos.
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All six blastocysts from O9 chimera #1 were iPS-cell derived suggesting that
this chimera was a pseudo-male. Additional genotyping identified 13/72 tested
blastocysts derived from iPS line O9 and 4/13 blastocysts derived from iPS line
O16 chimeras to carry the viral transgenes. The right panel shows that 3/8 tested
E.10 mid-gestation embryos were sired by a chimera derived from the donor iPS
line O16. + positive, - negative control samples.
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SUMMARY
Pluripotency can be induced in differentiated murine and human cells by
retroviral transduction of Oct4, Sox2, Klf4 and c-Myc. The resulting ‘induced
pluripotent stem’ (iPS) cells resemble embryonic stem (ES) cells in their
developmental potential and their epigenetic state. This direct reprogramming
approach could potentially lead to the development of ‘customized’ pluripotent
cell lines for human therapy and represents a valuable tool for basic research.
Further advances in the field, such as the development of virus-free
reprogramming strategies, would be greatly facilitated by a better understanding
of the molecular mechanism governing the reprogramming process. To this end,
we have devised a strategy in which the cDNAs of the four transcription factors
are under the transcriptional control of a doxycycline (dox) dependent promoter
in a lentiviral vector. We derived iPS cell lines from mouse fibroblasts using this
inducible system and determined the timing of known pluripotency marker gene
activation by FACS analysis. We found that alkaline phosphatase (AP) was
activated first, followed by stage specific embryonic antigen 1 (SSEA1).
Expression of Nanog and the endogenous Oct4 gene were only observed late in
the process, marking fully reprogrammed cells. We also discovered that the
virally transduced cDNAs needed to be expressed for at least 12 days in order to
generate fully reprogrammed cells. In contrast to previously used retroviral
constructs, which are efficiently silenced in iPS cells, the lentivirus-based vectors
employed in this study allow for continued overexpression of the viral transcripts
in iPS cells. We investigated the effect of sustained ectopic transgene expression
on the differentiation potential of different iPS cell lines harboring inducible or
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constitutively expressed viral transgenes and found that transgene silencing is a
prerequisite for normal cell differentiation. Our results are a step towards an
understanding of some of the molecular events underlying epigenetic
reprogramming.
INTRODUCTION
The generation of pluripotent cell lines from somatic cells has great potential for
basic research as well as clinical applications (Hochedlinger and Jaenisch, 2003;
Rideout et al., 2002). Even though epigenetic reprogramming of a somatic
genome to an embryonic state by nuclear transfer or fusion of ES cells with
somatic cells has become a widely used procedure in various mammalian
species over the last decade (Cowan et al., 2005; Kato et al., 1998; Polejaeva et
al., 2000; Tada et al., 2001; Wakayama et al., 1998; Wilmut et al., 1997), the
underlying molecular mechanism has not been identified.
It has been shown recently that retroviral transduction of mouse and human
somatic cells with four transcription factors initiates the gradual conversion of a
small subpopulation of the infected cells into a pluripotent, ES cell-like state
(Maherali et al., 2007; Meissner et al., 2007; Okita et al., 2007; Takahashi et al.,
2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007; Yu et al., 2007).
Mouse fibroblasts infected with murine Moloney Leukemia Virus (MLV) derived
vectors carrying the cDNAs of Oct4, Sox2, c-Myc, and Klf4 under the control of
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the viral long terminal repeat (LTR) region gave rise to ES cell-like iPS cell
colonies at a low frequency (Maherali et al., 2007; Meissner et al., 2007; Okita et
al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007). These iPS cells
were able to differentiate into cell types of all three germ layers in teratomas and
contributed to the germline of chimeric mice (Maherali et al., 2007; Okita et al.,
2007; Wernig et al., 2007). DNA methylation and histone modification analyses
revealed that the chromatin of iPS cells had been reprogrammed to an
embryonic state. This included demethylation of the endogenous promoters
controlling ES cell specific genes like Nanog and Oct4 (Maherali et al., 2007;
Okita et al., 2007; Wernig et al., 2007) and the simultaneous establishment of
both H3K4 and H3K27 tri-methylation marks at loci previously identified to be
‘bivalent’ in ES cells (Bernstein et al., 2006; Maherali et al., 2007; Wernig et al.,
2007). During the derivation process, iPS cells activated endogenous
pluripotency markers, such as Nanog, Oct4, Sox2, SSEA1 and AP, and
efficiently downregulated the transcriptional activity of the viral LTRs to basal
levels (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007), suggesting
that viral transgene expression becomes dispensable at a certain time point
during the reprogramming process. These findings in mouse together with the
recent derivation of human iPS cell lines let the development of customized
human cell therapy approaches appear within reach (Takahashi et al., 2007; Yu
et al., 2007). However, many problems remain unsolved.  One major obstacle is
that the stochastic activation of the viral transgenes has been linked to an
elevated frequency of tumor formation in iPS cell-derived chimeric mice (Okita et
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al., 2007). An in-depth understanding of the reprogramming process could
accelerate the development of virus-free iPS cell derivation strategies, which is
mandatory for clinical application of this technology.
In previous studies, iPS cell colonies were detected at widely differing time points
after infection of somatic cells. Depending on the selection strategy employed,
reprogrammed cells were identified as early as on day three and as late as
several weeks after infection (Maherali et al., 2007; Okita et al., 2007; Wernig et
al., 2007). Our recently published data demonstrated that cells originating from
the same infected parental cell activate the endogenous Oct4-locus at different
time points, suggesting that the induction of pluripotency by viral transduction is a
gradual process involving stochastic epigenetic events (Meissner et al., 2007).
Viral transduction-mediated reprogramming involves the transcriptional activation
of endogenous markers for pluripotency such as AP, SSEA1, Sox2, Oct4 and
Nanog (Maherali et al., 2007; Meissner et al., 2007; Okita et al., 2007; Wernig et
al., 2007). It is unclear, however, whether the reactivation of pluripotency-
associated genes is a random, stochastic process or follows a specific set of
sequential events and the minimal length of transgene expression required for
successful reprogramming has not been determined. Understanding the timing of
endogenous gene activation and transgene silencing is fundamental for the
development of transient, non-viral reprogramming strategies.
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In order to study the activation of endogenous genes during the reprogramming
process and the time requirements for ectopic expression of the four factors, we
have developed a lentiviral system in which the cDNAs of the four transcription
factors are driven from a dox-inducible promoter. In contrast to previously
employed retroviral systems (Maherali et al., 2007; Meissner et al., 2007; Okita et
al., 2007; Wernig et al., 2007) or MLV vectors paired with the dox-inducible
expression of Oct4 from a targeted allele (Maherali et al., 2007), this allows for
controlled expression of all four transgenes independent of viral integration and
cellular silencing of viral LTRs. We have derived iPS cell lines after infection of
fibroblasts obtained from Oct4-GFP knock-in mice or Nanog-GFP knock-in mice
expressing the M2rtTA from the endogenous Rosa26 (R26) promoter. By utilizing
inducible viruses, we were able to activate or downregulate the expression of the
four factors at different time points and to analyze the timing of the
reprogramming process. Using FACS analysis, we assessed the activation of the
four ES cell markers AP, SSEA1, Oct4-GFP and Nanog-GFP, and we observed
that SSEA1 expression marks an intermediate state of reprogramming whereas
Oct4 and Nanog expression was only detected in fully reprogrammed cells. We
also identified the minimum time of viral transgene expression required for
completion of the reprogramming process and determined the effect of continued
expression of the four factors on the differentiation potential of several iPS cell
lines.
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RESULTS
A dox-inducible system for the derivation of pluripotent cell lines
A lentiviral backbone for dox-inducible transgene expression was constructed by
replacing the human Ubiquitin-C promoter of the FUW plasmid (Lois et al., 2002)
with a tetracycline operator and minimal CMV promoter. The cDNAs for Oct4,
Sox2, Klf4, and c-Myc were subsequently cloned into this backbone. We
generated mouse embryonic fibroblasts (MEFs) carrying the R26 promoter-
driven M2rtTA (Beard et al., 2006) and a Green Fluorescent Protein (GFP) allele
driven by either the endogenous Oct4 or Nanog promoter (Maherali et al., 2007;
Meissner et al., 2007). M2rtTA(+/-);Oct4GFP(+/-) and M2rtTA(+/-);NanogGFP(+/-
) MEFs were infected with inducible Oct4, Sox2, c-Myc, and Klf4 viruses and
subsequently treated with dox (Figure 1A). To determine the expression levels of
the four genes from the inducible viruses, we performed quantitative PCR
analysis showing that ectopic transcript expression could be strongly induced in
the presence of dox (Supplementary Figure 1).
To generate iPS cell lines, 2.5x105 MEFs were infected in 10cm cell culture
dishes. The cultures were split 1:5 at three days after infection. Dox was added
to the cell culture medium one day following the split to induce transgene
expression and initiate the reprogramming process. In the presence of dox, the
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morphology of the infected MEFs changed within 3 days, with small, rounded
cells forming in the culture. Similar to previous observations (Maherali et al.,
2007; Meissner et al., 2007; Okita et al., 2007; Wernig et al., 2007) small
colonies were observed by day 9 and distinctively ES-like colonies appeared by
day 16, many of which had activated transcription of endogenous Oct4 or Nanog
indicated by  GFP expression. ES-like colonies were not observed in cultures
that had not been treated with dox. We picked single GFP-positive colonies from
the dox-treated plates at day 26 and expanded them on feeder MEFs in the
absence of dox to derive iPS cell lines (Figure 1B). Viable chimeras were
generated from both Oct4-GFP and Nanog-GFP iPS clones after injection into
Balb/c blastocysts (Figure 1C and D).
Sequential activation of pluripotency markers
In order to provide a baseline measure of endogenous ES cell marker activation
during the direct reprogramming of MEFs, we performed FACS analyses of AP,
SSEA1, and Oct4- or Nanog-driven GFP. For each experiment, Oct4-GFP and
Nanog-GFP cells were infected with the same batch of virus to reduce variability.
Three days after infection, the MEFs were split onto gelatin-coated 10cm plates.
The next day, dox was added to all plates (day 0). The expression of ES cell
specific markers was analyzed at various time points after dox addition up to day
35. The average percentages of cells expressing AP, SSEA1, Oct4-GFP or
Nanog-GFP from three independent experiments are displayed in Figure 2.
Representative FACS plots for AP and SSEA1/Oct4-GFP or SSEA1/Nanog-GFP
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analysis are displayed in Supplementary Figure 2. Since the GFP signal to
background fluorescence ratio was low, we performed autofluorescence
correction as outlined elsewhere (Alberti et al., 1987). Consistent with our
previous observations (Wernig et al., 2007), AP was reactivated early after
induction of the four factors and was detectable in a small percentage (~3-4%) of
cells at day 3. SSEA1 was first expressed in a subpopulation of cells (~4%) at
day 9 and GFP expression from either the Oct4 or Nanog endogenous promoters
was first observed by FACS at day 16, with the percentage of GFP positive cells
being below 1% in both cases. We performed quantitative RT-PCR assays to
investigate whether we could detect transcriptional activation of endogenous
Nanog or Sox2 loci before the detection of GFP fluorescence. We found that no
appreciable levels of either transcript could be detected by this assay at early
time points up to day 14 (Supplementary Figure 3).  The portion of cells
expressing AP, SSEA1 or GFP increased in both reporter lines over time,
consistent with our previous results (Wernig et al., 2007).
SSEA1 activation marks an intermediate step of reprogramming
The timing of marker appearance observed by FACS suggests that the activation
of AP, SSEA1, Oct4 and Nanog might be sequential events. This notion is
supported by the observation that at day 9 after infection only about 7% of the AP
positive cells also expressed SSEA1 and at day 16 only about 3% of the cells
staining for SSEA1 also expressed Nanog or Oct4 as indicated by GFP
fluorescence. In contrast, most if not all GFP positive cells also expressed
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SSEA1. To test the hypothesis that SSEA1 and Oct4/Nanog are sequentially
activated or that SSEA1 expression is required prior to Oct4 or Nanog activation,
we sorted infected populations of Oct4-GFP and Nanog-GFP cells at day 21 of
dox treatment (Figure 3A). Equal numbers of SSEA1+/GFP- cells were plated on
feeders and cultured for three days either in the presence or in the absence of
dox. After three days the medium was changed and the cells were incubated in
dox-free medium for an additional seven days. GFP positive colonies were
observed in both treated and untreated cultures of SSEA1+/GFP- cells (Figure
3B). The percentage of SSEA1+/GFP- cells that were able to generate GFP
positive colonies was calculated. In both the Oct4-GFP and the Nanog-GFP cell
populations ~0.02% of the SSEA1+/GFP- cells gave rise to GFP positive
colonies without dox treatment. This percentage increased about ten-fold to
~0.2% when the cells were treated with dox, indicating that continuous
expression of the transcription factors enhanced reprogramming in
SSEA1+/GFP- cells (Figure 3C). We confirmed the existence of SSEA1+/GFP+
cells in the sorted populations by FACS analysis on day 11 after the initial sorting
(Figure 3D). In contrast to SSEA1+/GFP- cells, SSEA1-/GFP- cells did not give
rise to any colonies after ten days of culturing them with or without dox.
To investigate whether the SSEA1+/GFP- cells that did not give rise to iPS cell
colonies after dox-withdrawal simply stopped dividing while maintaining SSEA1
expression or return to a MEF-like SSEA1-negative state, we repeated this
experiment. This time, however, we sorted cells after only 9 days of dox
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treatment - a time point well before the appearance of Nanog- or Oct4-GFP could
be observed. The SSEA1+/GFP- cells were seeded onto plates with feeders and
cultured for 20 days with or without dox. In addition, some of the SSEA1+/GFP-
cells were also seeded onto plates without feeders to allow for the analysis of
their morphology. At the end of the culture period, we assessed SSEA1 and GFP
expression by FACS analysis (Figure 4A). In contrast to the SSEA1+/GFP-
populations sorted at day 21, the populations sorted at day 9 did not give rise to
any SSEA1+/GFP+ cells after culturing them without dox, indicating the complete
absence of transgene-independent cells within the SSEA1+/GFP- populations
sorted at this earlier time point. Furthermore, most if not all cells cultured without
dox ceased to express SSEA1 and returned to a MEF-like morphology (Figure
4B). In contrast, when cultured in the presence of dox, the SSEA1+/GFP- cells
from day 9 gave rise to iPS colonies and yielded SSEA1+/GFP+ iPS cells at the
end of the culture period (Figure 4A and B).
Our results indicate that SSEA1 activation may represent an intermediate step
that may have to precede activation of Oct4 or Nanog in order for reprogramming
to be successful. The SSEA1-positive state is unstable and most SSEA1+/GFP-
cells depend on continued transgene expression to complete the reprogramming
process. When deprived of continued expression of the four transcription factors,
most cells cannot proceed further towards an embryonic state, but return to a
state resembling that of the donor cell. Our findings also indicate that
reprogramming is a gradual, asynchronous process and that continuous vector
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expression enhances reprogramming efficiency even at 21 days after the start of
dox induction, a time point well beyond the initial appearance of GFP positive iPS
cells.
Minimal time of transgene expression required for direct reprogramming
We investigated how long the exogenous expression of the four factors was
required for successful reprogramming of fibroblasts to dox-independent, self-
renewing iPS cells. For this, cells were infected with the inducible lentiviruses,
and split onto six gelatin-coated 10cm plates three days later as outlined in
Figure 5A. One day after splitting the cells, dox was added to the culture medium
(day 0). The drug was withdrawn from individual cultures at various time points
(day 12, 14, 16, 19, 22 and 26) and the dishes were fixed and stained for AP on
day 35 (Figure 5A). We found that day 14 was the earliest time point of dox-
withdrawal that was permissive to the establishment of dox-independent colonies
that stained positive for AP (Figure 5A). No dox-independent, AP positive
colonies were observed on plates that had dox withdrawn on day 12 (Figure 5A),
even though cell colonies were visible on those plates at the time of dox-
withdrawal. These initial colonies did not proliferate after dox-withdrawal and did
not stain for AP at day 35. In the dishes where dox was withdrawn at later time
points, the number of dox-independent, AP positive colonies increased with the
time that the cells were exposed to dox and therefore with the length of
transgene expression (Figure 5A).
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To determine the time point of dox-withdrawal at which fully reprogrammed iPS
cells could reproducibly be derived, we repeated this experiment in triplicate for
both Nanog-GFP and Oct4-GFP cells. This time we withdrew dox on days 9, 12,
14, 16, 21 and 24, respectively, and examined the plates for GFP expressing iPS
colonies on day 35 (Figure 5B). No marked differences in colony counts were
detected between Oct4-GFP and Nanog-GFP cells and the data obtained from
both donor cell lines were combined. We observed that dox-independent, GFP
expressing iPS cell colonies could not reliably be detected on plates that had dox
removed on or prior to day 12, with four of the six “day 12” plates containing no
GFP-positive colonies, one plate containing a single colony and another plate
containing two GFP-positive colonies. Notably, a number of small colonies were
visible on these early withdrawal plates at the time of dox removal
(Supplementary Figure 4A). However, these did not resemble ES cell colonies
and did not continue to proliferate once dox was withdrawn (Supplementary
Figure 4B). Dox-independent, GFP positive colonies consistently appeared on
plates treated with dox for 16 days or longer suggesting that some cells on those
plates could proliferate and self-renew independently of viral transgene
expression. Consistent with our results from the AP stainings displayed in Figure
5A, continued dox-treatment allowed more cells to reach this transgene-
independent state of the reprogramming process (Figure 5B). Together, these
results suggest that transgene expression is critical for the formation of iPS cells
at least up to day 12-16, and that the continued expression of the transgenes
beyond this time point increases the number of iPS cell colonies.  Shorter
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transgene expression yields cells that are AP and SSEA1 positive, as evident by
our FACS sorting experiments, but still depend on transgene expression for their
progress towards a fully reprogrammed iPS cell state.
Differentiation of iPS cells requires downregulation of transgene
expression
To test whether continuous transgene expression affected the differentiation
potential of the derived iPS lines, we compared three iPS cell lines derived using
inducible lentiviruses to iPS cell lines obtained after transduction of MEFS with
the four cDNAs cloned into the constitutively expressed FUW lentiviral vector
(Lois et al., 2002). In this vector, the cDNAs are expressed from the human
Ubiquitin C promoter that is ubiquitously expressed in mouse cells (Lois et al.,
2002). We injected 5x105 cells of three iPS lines harboring inducible vectors
(NS12, NS14, and NS16) and of five lines harboring constitutive vectors
subcutaneously into SCID mice.  We used wt ES cells and ES cells harboring the
R26-M2rtTA allele as controls. Figure 6 shows representative sections of ES-cell
and iPS-derived tumors that were stained for Oct4 expression. Whereas the
tumors obtained from the control ES cells and the inducible iPS cells displayed
similar states of differentiation, the tumors generated from iPS cell lines
harboring constitutively expressing vectors showed virtually no differentiated
cells. Most if not all cells in the FUW-derived iPS cell tumors stained strongly for
Oct4. This was in contrast to the controls and the tumors obtained after injection
of iPS cells harboring inducible vectors, where Oct4 was only expressed in very
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few cells throughout the tumor. These results suggest that continued ectopic
expression of the four transcription factors ablates the differentiation capacity of
iPS cell lines.
DISCUSSION
In this study, we used an inducible, lentiviral system to generate GFP positive,
pluripotent iPS cells from MEFs derived from Oct4-GFP/R26-M2rtTA and Nanog-
GFP/R26-M2rtTA knock-in mice. We established iPS cell lines that were able to
differentiate in teratoma assays and could produce viable chimeras. This is in
contrast to iPS cells harboring constitutively expressing lentiviral constructs that
are not efficiently silenced in iPS cells. The inducible system allowed us to
investigate the timing and sequence of ES cell marker gene activation using
FACS analysis. We found direct in vitro reprogramming to be a gradual process
encompassing the sequential activation of four pluripotency marker genes, with
AP being expressed first on day 3 followed by SSEA1 on day 9. GFP driven off of
the endogenous promoters of Oct4 or Nanog was first detectable on day 16
(Figure 7). SSEA1-/GFP- cells were not able to activate GFP expression in the
same time frame as SSEA1+/GFP- cells and the progress from the
SSEA1+/GFP- state to the dox-independent, fully reprogrammed SSEA1+/GFP+
state was greatly enhanced by continued transgene expression. Together, these
results indicate that SSEA1+/GFP- cells might represent a transgene-dependent
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intermediate state of reprogramming. Most of these partially reprogrammed cells
require continued transgene expression in order to progress towards a fully
reprogrammed state, whereas transgene downregulation causes them to stop
proliferating and to return to a fibroblast-like, SSEA1-negative state. Finally, we
demonstrated that the generation of iPS cells requires the ectopic expression of
the four transcription factors for a minimum of 12-16 days (Figure 7). The
removal of dox prior or on day 12 resulted in the return of virtually all colony-
forming cells to a MEF-like state. The independence from transgene expression
closely correlates with the reactivation of the endogenous Oct4 and Nanog loci
(Figure 7). We postulate, therefore, that the onset of endogenous Oct4 or Nanog
expression might be a marker for fully reprogrammed, transgene-independent
iPS cells.
The sequential activation of pluripotency marker genes found in this study is
consistent with our previous observations from MLV-based reprogramming
strategies where cells at day 14 after MLV-infection expressed AP and SSEA1,
but not Nanog, whereas cells had activated all three markers at day 20 (Wernig
et al., 2007). Intriguingly, Nanog-neo MEFs in that study yielded neomycin
resistant colonies even when the selection process was initiated at day 6 after
infection, a time point well before Nanog expression could be detected by
immunostaining (Wernig et al., 2007). Similar results were reported in Okita et
al., 2007, and Maherali et al., 2007, where puromycin resistant colonies were
derived from Nanog-GFP-IRES-puro MEFs by starting puromycin selection as
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early as 3 days after infection.  This discrepancy in timing between antibiotic
resistance and protein detection could be explained by the hypothesis that the
activation of pluripotency marker genes might be a drawn-out, gradual process,
with initial expression levels sufficient to render the respective, partially
reprogrammed cells resistant to antibiotics, but not high enough to warrant
detection by less sensitive methods like immunostaining, GFP assays or whole
population QPCR. This gradual activation seems to occur at different times for
specific markers, with AP and SSEA1 being activated earlier than Oct4 or Nanog
(Figure 7). It is also possible that the full activation of ‘early’ markers, such as AP
or SSEA1, is a prerequisite for the activation of ‘late’ genes, such as Oct4 and
Nanog. Both notions would be consistent with our finding that cells expressing
SSEA1, but not Oct4- or Nanog-promoter driven GFP may represent an
intermediate state of reprogramming.
We found the time span at which transgene expression becomes dispensable for
iPS cell derivation (12-16 days) to precede the time point at which GFP
expression indicating the activation of the endogenous Oct4 and Nanog loci
could be observed (day 16). Since GFP detection by FACS requires a significant
level of protein expression, it is likely that this method slightly overestimates the
minimum time span required for Nanog and Oct4 activation. This slightly delayed
detection could also explain our finding that SSEA1+/GFP- cell populations
sorted at day 21, but not those sorted at day 9, contained a small fraction of
transgene-independent cells. These cells might have activated the Oct4 or
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Nanog loci but did not display GFP expression levels high enough for FACS
detection. Sustained transgene expression beyond the minimal time requirement
increased the number of cells activating endogenous Nanog and Oct4
expression, supporting the idea of stochastic epigenetic events playing a role in
four-factor reprogramming. This is consistent with our previous observation that
infected cell populations continue to generate iPS colonies over a drawn-out time
window (Meissner et al., 2007). Our results suggest that individual cells either
enter the reprogramming process at different time points after transgene
induction or take different times to go through the reprogramming sequence.
Longer transgene expression, therefore, would give more cells the chance to
undergo the required stochastic epigenetic changes and, consequentially, reach
a state of transgene independence.
In previous reports on iPS cell derivation from somatic cells, transgene
expression was driven by the LTRs of MLV based vectors, which were shown to
be efficiently silenced in iPS cells (Maherali et al., 2007; Okita et al., 2007;
Wernig et al., 2007). When we used constitutively expressed lentiviral vectors to
generate iPS cell lines, we found these cells to be poorly capable to differentiate
normally in teratoma assays. This result supports the notion that efficient
transgene silencing is essential for the derivation of truly pluripotent iPS cell
lines. In a recent publication, iPS cell lines generated using constitutive lentiviral
vectors were reported to differentiate in teratoma assays and to contribute to
various tissues of mid-gestation chimeric fetuses (Blelloch et al., 2007). The
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cDNAs in that study were driven from the CMV promoter, which has been shown
to undergo methylation-mediated silencing in embryonic stem cells (Hong et al.,
2007; Xia et al., 2007), in contrast to the Ubiquitin C promoter employed in our
constitutively expressing viral constructs (Lois et al., 2002). It can be argued,
therefore, that the differentiation capabilities observed in iPS cells harboring
CMV-driven cDNAs could be a result of at least partial silencing of the viral
transgenes. Notably, no viable chimeras have been reported from iPS cell lines
derived using constitutive lentiviral constructs so far (Blelloch et al., 2007).
Very recently, it has been reported that mouse and human iPS cells can be
generated without the use of a c-Myc transgene (#add citations to
Endnote#Takahashi et al., 2007: Wernig et al., 2008; Yu et al., 2007). However,
the forced expression of c-Myc, as well as other factors such as Nanog and
Lin28, has been found to have a substantial effect on the efficiency and the
timing of the reprogramming process. While these reports are significant steps
towards reducing the tumorigenic potential of iPS cells and their derivatives, the
final solution to this problem will be the generation of transgene-free iPS cells.
The ability to quantify reprogramming dynamics in a controlled system as
presented here will be an invaluable tool for the development of transient
reprogramming strategies.
In conclusion, the results presented in this report clarify steps involved in the
generation of iPS cells by the expression of the four transcription factors Oct4,
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Sox2, Klf4 and c-Myc. The information on pluripotency marker activation and
transgene expression provided here can be utilized as a benchmark for further
analyses of the reprogramming process and should allow for the identification of
factors that positively affect epigenetic reprogramming. When compared to
nuclear transfer, it is obvious that reprogramming by viral transduction requires a
longer period of time, and it will be important to understand the molecular basis
for this difference. The determination of the minimum length of transgene
expression has implications for the development of non-retroviral delivery
methods of these four factors to derive genetically unmodified iPS cells.
Specifically, any transient expression strategy for iPS cell generation, such as
protein transduction, will need to provide protein expression at sufficient levels for
a minimum of 12-16 days. The generation of transient, non-viral approaches in
conjunction with a better understanding of the reprogramming process will be an
important step in the development of stem cell based therapies.
MATERIALS AND METHODS
Reporter cells
MEFs used in the infections with inducible lentiviruses were harvested at 13.5dpc
from F1 matings between R26-M2rtTA mice (Beard et al., 2006)and either Oct4-
GFP (Meissner et al., 2007) or Nanog-GFP mice (Maherali et al., 2007). MEFs
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used in the infections with constitutive lentiviruses were derived from matings of
mice carrying an Oct4-neomycin reporter allele (Wernig et al., 2007) and
expressed a p53 hairpin (Ventura et al., 2004).
Viral Constructs
To generate the tetracycline inducible viral backbone the human Ubiquitin C
promoter and intron were excised from FUW (Lois et al., 2002) by first digesting
with PacI, followed by 3' overhang removal with Klenow, and subsequent
digesting with BamHI. The Tet Operator/CMV promoter was excised from
pRevTRE (Clontech) by digesting first with BglII followed by fill-in followed by
BamHI digest. The TetO/CMV promoter and FUW backbone were then ligated.
The cDNAs for Oct4, Klf-4, Sox2 and c-Myc were subsequently cloned into the
EcoRI sites of the resulting vector. For the constitutive constructs, cDNAs were
cloned into the EcoRI site of FUW.
Cell Culture
Cells were cultured in standard ES-cell culture conditions in DMEM
supplemented with 10% FBS and LIF as described previously (Beard et al.,
2006).
Infections
Virus was prepared as previously described. Briefly, 293 cells were transfected
with a mixture of viral plasmid and packaging constructs expressing the viral
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packaging functions and the VSV-G protein. Medium was replaced 24hrs after
transfection and viral supernatants were collected at 48hrs and 72hrs. After
filtration, supernatants were pooled and MEFs were incubated with viral
supernatants and fresh media at a ratio of 1:1 for 24 hours and subsequently
cultured in ES-cell medium.
Blastocyst Injections
Injections of iPS cells into Balb/c host blastocysts were carried out as previously
described (Beard et al., 2006).
Antibodies
For FACS analysis we used an APC conjugated anti-mouse SSEA1 (R&D
systems, Minneapolis, MN) and an alkaline phosphatase substrate kit: Vector
Red substrate kit (Vector Laboratories, Burlingame, CA).
FACS
Cells were trypsinized, washed once in PBS and resuspended in FACS buffer
(PBS+5%CCS).  106 cells were stained with 10ul of anti-SSEA1 antibody for 30
minutes and for the stains that included the AP substrate, cells were then
washed once in PBS and fixed/permeabilized using an intracellular staining kit
(R&D systems, Minneapolis, MN).  After permeabilization, cells were treated with
500ul of AP substrate solution (Vector Laboratories, Burlingame, CA) for 20
minutes. Cells were then washed once with wash buffer and resuspended in
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FACS buffer for analysis on a FACS-calibur cell sorter. For live sorting, cells
were stained with an APC-conjugated antibody against SSEA1 (R&D systems,
Minneapolis, MN) and sorted on a FACS-Aria cell sorter.
Teratoma assay
Cells were trypsinized and 5x105 cells were injected subcutaneously into SCID
mice. After 14-21 days, teratomas were dissected, fixed in 10% phosphate-
buffered formalin overnight and subsequently embedded in paraffin wax using a
Tissue-Tek VIP embedding machine (Miles Scientific, Naperville, IL) and a
Thermo Shandon Histocenter 2 (Thermo Fisher Scientific, Waltham, MA).
Sections were cut at a thickness of 2 µm using a Leica RM2065 (Leica, Wetzlar,
Germany) and stained with hematoxylin and eosin or antibodies against Oct4 as
previously described(Hochedlinger et al., 2005).
Quantitative RT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). Five
micrograms of total RNA was treated with DNase I to remove potential
contamination of genomic DNA using a DNA Free RNA kit (Zymo Research,
Orange, CA). One microgram of DNase I-treated RNA was reverse transcribed
using a First Strand Synthesis kit (Invitrogen) and ultimately resuspended in 100
ul of water. Quantitative PCR analysis was performed in triplicate using 1/50 of
the reverse transcription reaction in an ABI Prism 7000 (Applied Biosystems,
Foster City, CA) with Platinum SYBR green qPCR SuperMix-UDG with ROX
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(Invitrogen). Primers used for amplification were as follows: Oct4 F, 5_-
ACATCGCCAATCAGCTTGG-3_ and R, 5_-AGAACCATACTCGAACCACATCC-
3_; c-myc F, 5’-CCACCAGCAGCGACTCTGA-3’ and R, 5’-
TGCCTCTTCTCCACAGACACC-3’; Klf4 F, 5’-GCACACCTGCGAACTCACAC-3’
and R, 5’-CCGTCCCAGTCACAGTGGTAA-3’; Sox2 F, 5’-
ACAGATGCAACCGATGCACC-3’ and R, 5’-TGGAGTTGTACTGCAGGGCG-3’.
To ensure equal loading of cDNA into RT reactions, GAPDH mRNA was
amplified using the following: F, 5_-TTCACCACCATGGAGAAGGC-3_; and R,
5_-CCCTTTTGGCTCCACCCT-3_. Data were extracted from the linear range of
amplification. All graphs of qRT-PCR data shown represent samples of RNA that
were DNase treated, reverse transcribed, and amplified in parallel to avoid
variation inherent in these procedures.
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FIGURE LEGENDS
Figure 1:  Derivation of iPS cells using an inducible lentiviral system.
Somatic cells harboring a GFP reporter driven by the endogenous Oct4 or Nanog
promoters were infected with tet-inducible lentiviral vectors carrying the cDNAs of
Oct4, Sox2, Klf4 and c-Myc (A). The addition of doxycycline after infection
induced lentiviral expression and subsequently led to reprogrammed, GFP
positive iPS cell colonies (B). The iPS cells were pluripotent and contributed to
viable chimeras after injection into Balb/c host blastocysts as indicated by coat
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color (C, D). White mice are non-chimeric Balb/c animals, whereas mixed coat
color mice are chimeric.
Figure 2: Timing of pluripotency marker reactivation during
reprogramming.
FACS analysis of AP, SSEA1 and GFP reactivation was performed on
NanogGFP/M2rtTA MEFs and Oct4GFP/M2rtTA MEFs at different times after the
induction of reprogramming. Cells were harvested at various time points after the
addition of dox to the ES cell medium and incubated with an APC labeled anti-
SSEA1 antibody and a fluorescent substrate that is activated in the presence of
AP activity. The data from three independent experiments is summarized.
Columns display average percentages of cells expressing AP (yellow columns),
SSEA1 (blue columns) and Nanog-GFP (black columns) or Oct4-GFP (white
columns). AP and SSEA1 values represent averages of Nanog-GFP and Oct4-
GFP experiments. Error bars indicate standard deviations.
Figure 3: SSEA1 expression marks an intermediate state of
reprogramming.
SSEA1+/GFP- cells were sorted with an APC conjugated SSEA1-antibody after
21 days of transgene expression and seeded on feeder MEFs (A). GFP positive
ES-like cell colonies were observed ten days after sorting (B). Supplementation
of the media with dox for an additional three days after sorting increased the
percentage of SSEA1+/GFP- cells that gave rise to GFP positive iPS cell
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colonies (C). Confirmation of GFP-positive cells in the sorted SSEA1+/GFP-
populations eleven days after initial sorting and seeding on feeder MEFs (D).
Figure 4: SSEA1+/GFP- cells return to a MEF-like state upon dox withdrawal
Oct4GFP/M2rTTA MEFs undergoing reprogramming were FACS sorted for
SSEA1 expression after 9 days of transgene expression (A). The cells were
cultured either in the presence or absence of dox for 20 days after the intial
sorting and then re-analyzed for SSEA1 and GFP expression. While plates that
were treaed with dox contained SSEA1+/GFP+ and SSEA1+/GFP- cells, virtually
all cells on untreated plates had lost their SSEA1 expression (A). After culture,
Culture in the presence of dox yielded ES-like colonies, but in the absence of dox
the SSEA1+/GFP- cells returned to a MEF like morphology (B).
Figure 5: Time requirement of transgene expression for iPS derivation.
Infected MEFs were split into 6 dishes and cultured in the presence of dox for a
different number of days as indicated by numbers next to the red lines (A). Dox
was withdrawn at different time points as indicated by red bars and the cells were
subsequently cultured in the absence of the drug until day 35. On day 35 all
plates were stained for AP at ay 35 of reprogramming to determine how many
transgene-independent cells existed at the time point of dox withdrawal. No AP
positive colonies were observed when dox was withdrawn before day 12 and the
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number of AP positive colonies increased with the time the cells were exposed to
the drug (A). Similarly, infected MEFs were grown in the presence of dox and dox
was removed at different time points from the culture medium. GFP expressing
iPS colonies were counted on day 35. Data for Nanog-GFP and Oct4-GFP
experiments were averaged and the number of colonies detected in six wells (3
for Oct4-GFP and 3 for Nanog-GFP cells) for each time point is shown in the bar
graph (B). Error bars indicate standard deviation.
Figure 6: Constitutive expression of the four factors prevents
differentiation of iPS cells in teratomas.
Differentiation of iPS cells in teratomas was ablated by continuous expression of
transgenes in iPS cells. Tumors derived from iPS cells expressing the four
transgenes under the control of the constitutive Ubiquitin C promoter stained
homogeneously positive for Oct4 and did not show normal cell differentiation (A).
IPS cells harboring the inducible viral backbones differentiated readily after
downregulation of the transgenes in the absence of dox (B). The tumors derived
from these cells were similar in size, fraction of cells staining positive for Oct4
and differentiation to tumors derived from wildtype control ES cell lines (C) or ES
cells harboring the R26-M2rtTA allele (D).
Figure 7: A timeline of reprogramming dynamics.
The black arrow represents the time starting from infection (above) or dox-
induction (below) in one-day increments. For MLV infection, the earliest time
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points for two antibiotic selection strategies are indicated by blue bars and the
expression of Nanog-GFP and Oct4-GFP is indicated by green bars. For dox-
inducible transgenes, the minimum time of dox-induced transgene expression for
successful iPS cell derivation is displayed as a black bar. The expression timing
of four pluripotency marker genes is indicated by red (AP and SSEA1) and green
bars (Nanog-GFP and Oct4-GFP)
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Somatic cells can be reprogrammed to induced pluripotent stem (iPS) cells by
retroviral transduction of four transcription factors, Oct4, Sox2, Klf4 and c-Myc
(Takahashi et al., 2006; Takahashi et al., 2007; reviewed in Jaenisch and Young,
2008). While the reprogrammed pluripotent cells are thought to have great
potential for regenerative medicine (Hanna et al., 2007; Wernig et al., 2008b),
genomic integrations of the retroviruses, especially c-Myc, increase the risk of
tumorigenesis (Okita et al., 2007).  Recently, iPS cells have been generated
without c-Myc retrovirus (Myc[-]), but in the absence of exogenous c-Myc the
efficiency and kinetics of reprogramming are significantly reduced (Nakagawa et
al., 2008; Wernig et al., 2008a).  We report here that soluble Wnt3a promotes the
generation of iPS cells in the absence of c-Myc retrovirus.  These data
demonstrate that signal transduction pathways and transcription factors can act
coordinately to reprogram differentiated cells to a pluripotent state.
Naturally occurring signaling molecules that modulate the expression of
endogenous ES cell transcription factors are promising candidates for soluble
factors that enhance reprogramming. The Wnt signaling pathway contributes to
the maintenance of pluripotency in mouse and human ES cells (Sato et al., 2004;
Ogawa et al., 2006; Singla et al., 2006; Cai et al., 2007), as well as the self-
renewal of undifferentiated adult stem cells in multiple tissues (Reya and Clevers,
2005). In addition, initial studies of iPS cell generation suggested that
constitutively active b-catenin, another downstream component of the Wnt
pathway, might promote reprogramming of fibroblasts to pluripotency (Takahashi
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and Yamanaka, 2006).  Studies of Tcf3, one of the key transcriptional regulators
downstream of the Wnt pathway in embryonic stem cells, have revealed that this
factor co-occupies almost all promoter regions occupied by ES cell specific
transcription factors, including Oct4 and Nanog, and can regulate the expression
of key ES cell transcription factors (Cole et al, 2008; Tam et al., 2008; Yi et al.,
2008).
Since the Wnt pathway is intimately connected to the core circuitry of
pluripotency, we hypothesized that the stimulation of the pathway using soluble
factors could modulate the efficiency of inducing pluripotency in somatic cells.
Here we examined the influence of Wnt stimulation on the reprogramming of
murine fibroblasts in the absence of c-Myc retrovirus.  For this, cells with GFP
driven by the endogenous Oct4 promoter (Meissner et al., 2007) were infected
with doxycycline (DOX)-inducible lentiviruses encoding Oct4, Sox2 and Klf4.
Oct4/Sox2/Klf4 infected cells were either cultured in standard ES cell medium or
in Wnt3a-conditioned medium (Wnt3a-CM) and were analyzed for GFP
expression by flow cytometry at days 10, 15 and 20 after DOX induction.  No
GFP positive cells were present with or without Wnt3a-CM treatment on day 10
or day 15.  By day 20 a small population of GFP expressing cells was detected
only in the cells cultured in Wnt3a-CM (Figure 1a). The Wnt3a-CM exposed
cultures formed GFP expressing colonies with morphology typical for ES or iPS
cells (Figure 1b).  However, unlike four-factor-transduced cells, which usually
form a highly heterogeneous population of cells when propagated without
selection, the Oct4/Sox2/Klf4/Wnt3a-CM colonies appeared homogenously ES-
like, similar to previously reported Myc[-] iPS clones (Nakagawa et al., 2008).
Several assays were performed to characterize the developmental potential
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of Myc[-] iPS cells derived with Wnt3a-CM treatment.  Immunocytochemistry
confirmed the expression of markers of pluripotency, including the nuclear factor
Nanog and the surface glycoprotein SSEA1 (Figure 1b).  Functional assays
confirmed that, like ES cells, these iPS cells were pluripotent.  When injected into
SCID mice subcutaneously, the Myc[-] iPS cells gave rise to teratomas with
histological evidence of cells differentiating into all three germ layers (Figure 1c).
More importantly, Myc[-] iPS cells derived with Wnt3a-CM treatment contributed
to the formation of somatic tissues as well as the germline in chimeric mice
(Figures 1d and 1e and Supplemental Table S1).  These results indicate that
Wnt3a-CM treated Myc[-] clones are pluripotent cells that are morphologically and
functionally indistinguishable from ES cells.
To quantify the effects of Wnt3a-CM, triplicate experiments were
performed on Oct4/Sox2/Klf4-inducible MEFs carrying a G418 resistance
cassette downstream of the Oct4 promoter (Figure 2a).  G418 was added to the
cultures at 15 days after infection to select for cells that had reactivated the Oct4
locus.  When scored on day 28 after infection, only a few Myc[-] G418 resistant
colonies (between 0-3 colonies forming on each ten centimetre plate) were
detected in standard ES cell culture conditions. In contrast, ~20 fold more drug
resistant colonies formed when G418 selection was initiated on Wnt3a-CM-
treated cells, consistent with the conclusion that activation of the Wnt pathway
enhances reprogramming.  It should be noted that conditioned medium from
control fibroblasts (L cells, ATCC) lacking Wnt3a over-expression also caused a
moderate increase in the number of G418-resistant colonies relative to standard
ES medium, suggesting that normal fibroblasts may secrete factors, perhaps
including Wnt3a, that promote reprogramming.  So far, we have been unable to
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recapitulate the effects of Wnt3a-CM on reprogramming with small molecule
inhibitors of glycogen synthase kinase-3 (Gsk3) that modulate the Wnt pathway
and promote the self-renewal of ES cells (Sato et al., 2004; Ying et al., 2008)
(Supplementary Figure S1). While there are many plausible explanations for
this negative result, one possibility is that the half-life of these chemicals is too
short to provide sustained stimulation of the Wnt-pathway required to enhance
reprogramming.
To independently assess the effect of Wnt3a on reprogramming, we
cultured cells in the presence of ICG-001 (Teo et al., 2005; McMillan and Kahn,
2005), an inhibitor of the Wnt/ß-catenin pathway.  Figure 2a (right columns)
shows that 4µM ICG-001 strongly inhibited the effect of Wnt3a-CM on Myc[-] iPS
formation.  The effects of Wnt3a-CM and ICG-001 were also examined in MEFs
over-expressing all four reprogramming factors, including c-Myc (Figure 2b).
High numbers of G418 resistant colonies were observed in both standard ES cell
media (66 colonies/32cm2) and Wnt3a-CM in four-factor-reprogrammed cells,
with only a subtle increase in the number of colonies with Wnt3a-CM (80
colonies/32cm2).  In contrast to the dramatic effect of ICG-001 on Myc[-] cells, at
the same dose, the compound had only a subtle effect on the number of G418
colonies in c-Myc transduced cells, and a relatively high number of resistant
colonies was observed under these conditions (51 colonies/32cm2) (Figure 2b).
When the experiment was repeated with higher doses of ICG-001, iPS colony
numbers were further reduced, but even at 25µM multiple Oct4/Sox2/Klf4/c-Myc
iPS colonies were observed (mean= 8 colonies/32cm2) (Supplemental Figure
S2). These data suggest that Wnt signaling and c-Myc could have overlapping,
but not completely redundant roles in the induction of pluripotency.
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Recent reports have demonstrated that Myc is dispensable for inducing
pluripotency in MEFs (Nakagawa et al., 2008; Wernig et al., 2008a), establishing
Oct4, Sox2 and Klf4 as a core set of reprogramming factors, although a slightly
different combination of factors also functions in human cells (Yu et al., 2007).
Epigenetic reprogramming of MEFs with defined factors is a gradual process,
where transcription factors progressively re-establish the core circuitry of
pluripotency over the course of weeks (Brambrink et al, 2008; Stadtfeld et al.,
2008).  Myc accelerates this process (Nakagawa et al., 2008; Wernig et al.,
2008a), conceivably because it enhances cell proliferation allowing the changes
to unfold more rapidly.  Additionally, Myc is suspected to have widespread effects
on chromatin state (Knoepfler, 2008; Kim et al., 2008) and could facilitate the
productive binding of the core reprogramming factors to their appropriate
genomic targets (Jaenisch and Young, 2008).
The Wnt signaling pathway has been shown to connect directly to the core
transcriptional regulatory circuitry of ES cells, suggesting a mechanism by which
this pathway could directly promote the induction of pluripotency in the absence
of c-Myc transduction (Figure 2c).  In ES cells, Tcf3 occupies and regulates the
promoters of Oct4, Sox2 and Nanog (Cole et al., 2008; Tam et al., 2008; Yi et al.,
2008).  In MEFs, these endogenous pluripotency transcription factors are
silenced.  During reprogramming, as exogenous Oct4, Sox2 and Klf4 contribute
to the reactivation of the endogenous pluripotency factors (Jaenisch and Young,
2008), Wnt signaling could directly potentiate the effect of these transcription
factors, as it does in ES cells (Cole et al., 2008).
Additionally, Wnt could serve to activate endogenous c-Myc directly,
thereby substituting for exogenous c-Myc (Figure 2c).  Indeed, c-Myc is a well-
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established target of the Wnt pathway in colorectal cancer cells (He et al., 1998).
In ES cells, Tcf3 occupies the c-Myc promoter, and Wnt3a positively contributes
to expression of the gene (Cole et al., 2008). However, quantitative PCR studies
did not reveal Wnt3a-CM-dependent activation of c-Myc during the first 48 hours
after induction of Oct4/Sox2/Klf4 in MEFs (Supplementary Figure S3).
Although we cannot exclude that Wnt3a enhances c-Myc expression in the rare
cells that will eventually become iPS cells, the expression data suggest that the
role of Wnt in reprogramming could be independent of c-Myc induction,
consistent with recent findings in ES cells (Ying et al., 2008). Wnt signaling and
c-Myc could play partially redundant functional roles in iPS cell generation.  For
example, Wnt-induced effects on cell proliferation could help to accelerate the
sequence of events that lead to the generation of Myc[-] iPS colonies.
A major goal of current research is to identify transient cues that can
reprogram somatic cells, eliminating the need for retroviruses.  The studies
described here establish that Wnt stimulation can be used to enhance the
efficiency of reprogramming in combination with nuclear factors, Oct4, Sox2 and
Klf4. By enhancing the efficiency of reprogramming in the absence of c-Myc
retrovirus, soluble Wnt, or small molecules that modulate the Wnt signaling
pathway, will likely prove useful in combination with other transient cues, yet to
be identified, that can replace the remaining retroviruses.
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Figure Legends
Figure 1 Wnt3a promotes reprogramming of somatic cells to pluripotency.
a.  Scatter plots comparing GFP intensity to autofluoresence, using flow
cytometry, in Oct4-GFP cells on day 20 post-induction of Oct4/Sox2/Klf4, reveal
a GFP expressing population of cells (indicated with an arrow) only with Wnt3a-
CM treatment (right), not in the control (Ctrl) Oct4/Sox2/Klf4-infected cells
cultured in standard ES cell medium (left). b. Phase-contrast micrographs
(Phase, left) of GFP expressing Myc[-] cells derived with Wnt3a-CM treatment
and without any genetic selection.  Immunostaining reveals induction of
pluripotency markers, Nanog (upper) and SSEA-1(lower) in Wnt3a-CM treated
Myc[-]  cells. c. Wnt3a-CM treated Myc[-] lines formed teratomas when injected into
SCID mice subcutaneously.  Teratomas from Oct4/Sox2/Klf4/Wnt3a-CM iPS
lines showed evidence of differentiated cells of three germ layers similar to
teratomas formed from V6.5 mES injections. Arrows indicated neural tissue in
(upper), cartilage in (middle), and endodermal cells in (lower),   d.
Oct4/Sox2/Klf4/Wnt3aCM iPS lines derived without selection gave rise to
chimeric mice (as shown on the left) with agouti coat color and pigmented eyes
(in contrast to wild type Balb/c mouse, right) providing evidence of contribution to
somatic cells.  e. Agouti coat color of offspring (left) of chimeric mouse (right)
confirmed that the Oct4/Sox2/Klf4/Wnt3a-CM iPS line generated here is
germline-competent.
Figure 2 Wnt/ß-catenin stimulation enahances iPS colony formation in
absence of c-Myc retrovirus.  a.  Counts are shown for G418-resistant colonies
in Oct4/Sox2/Klf4 over-expressing MEFs cultured in ES cell media, control L cell
conditioned media (ATCC), Wnt3a over-expressing conditioned media (ATCC),
and Wnt3a over-expressing conditioned media with ICG-001 (4µM).  Selection
was initiated on day 15 post-induction, and colonies were assessed on day 28.
Wnt3a-CM treatment was maintained for 6-9 days after selection was initiated.
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Mean number of counts from triplicate experiments is displayed with error bars
indicating S.D. b. Counts are shown for G418-resistant colonies (in a 32cm2
area) in Oct4/Sox2/Klf4/c-Myc over-expressing MEFs cultured in ES cell media,
Wnt3a over-expressing conditioned media (ATCC), and Wnt3a over-expressing
conditioned media with ICG-001 (4µM). Selection was initiated on day 10 post-
induction, Wnt3a-CM was maintained for the first 6-9 days of selection, and
colonies were assessed on day 20.  c. Wnt stimulation promotes the formaton of
iPS cells in the absence of c-Myc transduction.  This could be due to: i) direct
regulation by the Wnt pathway of key endogenous pluripotency factors, such as
Oct4, Sox2 and Nanog as suggested by genomic studies in ES cells (Cole et al.,
2008), ii) Wnt pathway-induced activation of endogenous Myc (He et al., 1998;
Cole et al., 2008), or other cell proliferation genes, accelerating the sequential
process of forming iPS colonies.
136
aFigure 1
b
c d
e
Oct/Sox2/Klf4
Mesoderm
Ectoderm
Endoderm
GFP
au
to
flu
or
es
en
ce
Wnt3a-CMCtrl
101 102 103101
101
102
103
101
102
103
102 103
0.00% GFP+ 0.33% GFP+
Phase
Phase
Hoechst
Hoechst
Nanog
SSEA1
137
Figure 2
a
c
b
?
ICG-001
138
Chapter  5
Reprogramming of murine fibroblasts to iPS cells: Chemical
Complementation of Klf4
Costas A. Lyssiotis1, Ruth K. Foreman1, Judith Staerk1, Michael Garcia, Divya Mathur,
Styliani Markoulaki, Jacob Hanna, Luke L. Lairson, Bradley D. Charette, Laure C.
Bouchez, Michael Bollong, Conrad Kunick, Achim Brinker, Charles Cho, Peter G.
Schultz2 and Rudolf Jaenisch2
1These authors contributed equally to this work.
2Corresponding authors
Author contributions: CAL, RF and JS contributed to the concept, designed and
performed the experiments, analyzed the data, and wrote the manuscript. MG helped in
design of and ran the primary small molecule screen. DM, SM, JH, LLL, BDC, LCB and
MB contributed reagents and/or provided technical assistance. CK contributed analytical
tools. AB and CC contributed to the design of the screening platform. PGS and RJ
provided the concept, assisted in experimental design and analysis, and revised the
manuscript.
139
Summary
Ectopic expression of defined transcription factors can reprogram somatic cells to
induced pluripotent stem (iPS) cells, but the utility of iPS cells is hampered by the use of
viral delivery systems. Small molecules offer an alternative to replace virally transduced
transcription factors with chemical signaling cues responsible for reprogramming. In this
study we describe a small molecule screening platform that was applied to identify
compounds that functionally replace the reprogramming factor Klf4. A series of small
molecule scaffolds were identified that activate Nanog expression in mouse fibroblasts
transduced with a subset of reprogramming factors lacking Klf4. Furthermore,
application of one such molecule, kenpaullone, in lieu of Klf4, gave rise to iPS cells that
are indistinguishable from murine embryonic stem cells. This experimental platform can
be used to screen large chemical libraries in search of novel compounds to replace the
reprogramming factors that induce pluripotency. Ultimately, such compounds may
provide mechanistic insight into the process of reprogramming.
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Recently it has been demonstrated that forced expression of combinations of four
transcription factors – Oct4, Klf4, Sox2 and c-Myc or Oct4, Sox2, Nanog and Lin28 –
can reprogram somatic cells into induced pluripotent stem (iPS) cells that closely
resemble embryonic stem (ES) cells (Maherali et al., 2007; Okita et al., 2007; Takahashi
and Yamanaka, 2006; Wernig et al., 2007). The induction of pluripotency in somatic
cells by ectopic expression of four transcription factors has created new opportunities in
the stem cell field. For example, patient-derived pluripotent cells may ultimately
represent a personalized source of tissue to replace cells lost to degenerative or age
associated diseases (Jaenisch and Young, 2008). However, the clinical use of iPS cells
is mainly hindered by the use of virally transduced transcription factors and the use of
proto-oncogenes.
Optimization of the original reprogramming method has achieved reprogramming of
both mouse and human somatic cells with the three-factor combination of Oct4, Sox2
and Klf4 in the absence of c-Myc (Hockemeyer et al., 2008; Nakagawa et al., 2007;
Wernig et al., 2008b). Additional methods to reduce the number of reprogramming
factors have taken advantage of endogenously expressed reprogramming factors,
thereby replacing the need for ectopic expression of these factors – e.g., Sox2 (Aasen
et al., 2008; Aoi et al., 2008; Eminli et al., 2008; Kim et al., 2009; Kim et al., 2008b).
More recently, iPS cells have been generated by the use of excisable vectors (Kaji et
al., 2009; Soldner et al., 2009; Woltjen et al., 2009), non-integrating vectors (Stadtfeld et
al., 2008; Yu et al., 2009) or transient transfection approaches (Okita et al., 2008). While
these methods have solved some of the limitations posed by the presence of multiple
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proviruses in the genome of iPS cells, they either remain inefficient or have failed to
further our understanding of the mechanistic details involved epigenomic
reprogramming.
Small molecules that induce epigenetic changes have also been used to increase
the efficiency of reprogramming and/or replace reprogramming factors (Huangfu et al.,
2008a; Huangfu et al., 2008b; Mikkelsen et al., 2008; Shi et al., 2008a; Shi et al., 2008b;
Wernig et al., 2008a). Recently, the histone deacetylase inhibitor valproic acid enabled
two-factor reprogramming (Oct4 and Sox2) of human fibroblasts in the absence of Klf4
and c-Myc (Huangfu et al., 2008a; Huangfu et al., 2008b). This method relies on the use
of known molecules that target known mechanisms. The identification of novel small-
molecules that induce pluripotency could provide useful chemical tools to unravel and
study the molecular mechanisms governing this process. Furthermore, application of
such molecules may ultimately lead to useful new therapeutics for the treatment of
disease. Toward this end, we have developed a high-throughput screening strategy to
identify small molecules that can functionally replace reprogramming transcription
factors. In this paper we describe the identification of a series of compounds that can
substitute for the reprogramming factor Klf4 in the formation of iPS cells. Our results
provide proof-of-principle that high-throughput screening is a robust vehicle to identify
small-molecules that can replace the transcription factors used to reprogram somatic
cells.
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Results
Nanog-luciferase reporter mouse strain. The induction of pluripotency in fibroblasts
by the ectopic expression of Oct4, Sox2, Klf4 and c-Myc requires a minimum of 8-12
days and occurs at low frequency with <0.1% of the somatic cells giving rise to iPS cells
(Brambrink et al., 2008; Wernig et al., 2007). The slow kinetics of reprogramming
impedes the development of robust assays to screen large chemical libraries with a
reliable readout that can be captured on a well-to-well basis in a miniaturized format. In
order to overcome these limitations, we relied on the high sensitivity and quantitative
readout capabilities of luciferase to develop a screening platform. To establish a
sensitive readout for iPS cell formation, the firefly luciferase gene was inserted into the
Nanog locus by homologous recombination. Nanog was chosen because it plays
important roles in the maintenance of the undifferentiated state (Chambers et al., 2003;
Chambers et al., 2007; Mitsui et al., 2003), is completely inactivated in somatic
lineages, and iPS cells selected for Nanog reactivation demonstrate complete
developmental potential (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007).
A targeting vector was constructed using 1.2kb of the Nanog promoter as a 5' arm
and 1.4kb of Nanog intron 2 as a 3' arm. The firefly luciferase gene from pGL3-basic
and a floxed pgk-neo cassette were inserted between the targeting arms (Fig. 1A).
Nanog-luciferase (NL) ES cell clones that carried the targeting construct in the Nanog
locus, as confirmed by Southern blot analysis (Fig. 1B), gave rise to a signal 10-30
times greater than wild type V6.5 ES cells (Fig. 1C). The NL ES cells were introduced
into blastocysts to generate chimeric mice, which were bred to generate both transgenic
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mice and mouse embryonic fibroblasts (MEFs). NL-MEFs produced negligible amounts
of luciferase (Fig. 1C) and were used for subsequent experiments.
High-throughput chemical screening strategy: Klf4 replacement. In this report, we
customized our screening strategy to identify compounds that would replace Klf4. It has
been suggested that Klf4 plays a major role in chromatin remodeling and recent
evidence demonstrated that Klf4 is an important mediator of the undifferentiated of ES
cell state (Jiang et al., 2008; Kim et al., 2008a). In addition, over-expression of Klf4 can
promote breast cancer (Foster et al., 2000) or squamous cell carcinomas (Foster et al.,
2005) ascribing a potent oncogenic role to this transcription factor. Thus, replacement of
Klf4 is a critical step for the eventual application of iPS cells as a therapeutically viable
strategy.
In order to identify a chemical replacement for Klf4, NL-MEFs were transduced with
a subset of reprogramming factors consisting of Oct4, Sox2 and c-Myc (OSM). To
obtain the approximately 109 cells needed to screen large chemical libraries required
that OSM transduced NL-MEFs be expanded for three passages prior to screening. At
passage 4, OSM transduced NL-MEFs were seeded into 1536-well plates at 500
cells/well in mouse ES cell growth media supplemented with LIF (20 ng/mL) and
screened against a large (500,000 compounds), chemically diverse small molecule
library (Plouffe et al., 2008). Compounds were added at a final concentration of 2.2 µM
(20 nL of 1 mM stock solutions in 9 µL of media) immediately after plating, and Nanog-
driven luciferase expression was assayed 10 days later (Fig. 1D). Analysis of a focused
library in pilot experiments demonstrated a high degree of homogeneity in luciferase
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response from well to well (104 molecules in triplicate; SI Fig. 1). Furthermore,
normalization of these data using the ‘jackknife’ Z score method – which accounts for
plate to plate variation and does not rely on positive controls readings – and subsequent
analysis using the one-sample Kolmogorov-Smirnov test (P = 0.54) indicated that there
was little difference between the empirical and theoretical inverse gamma distribution.
These statistical analyses confirmed both that the screening platform was robust and
that the output data were highly reliable (Malo et al., 2006).
Nanog activity from OSM transduced NL-MEFs was one order of magnitude greater
than that in non-transduced cells and 4-fold less than the activity in pluripotent NL
reporter cells (Fig. 1D). From the primary screen, compounds that gave rise to a signal
>2.2-fold (~5K compounds) over the plate average –assuming that most compounds
are inactive and can serve as controls (Malo et al., 2006) – were selected for reanalysis
in triplicate. Measurements with these putative hit compounds were collected, averaged
and those that activated the luciferase signal 2.5-fold over DMSO treated controls (~1K
compounds) were counter-screened in a cell based SV40-driven firefly luciferase assay
to rule out false positives that directly and non-specifically activate luciferase reporters
(Auld et al., 2009). Compounds that reproducibly hit in the Nanog assay that did not hit
in the SV40 assay were further analyzed in a dose response format to identify the
optimal concentration for activity (Fig. 2A). Collectively, this strategy further narrowed
our hit compounds to 135 small molecules (~0.03% of the initial set), which grouped into
three lead structural classes – flavones, lysergamides, and paullones (Fig. 2B).
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Activity of lead compounds. To distinguish compounds that replace Klf4 from those
that simply activate Nanog expression, colony formation was used as a secondary
assay. Representative compounds from each of the lead structural classes were added
to OSM transduced MEFs and analyzed for the presence of colonies 10 days later.
Members of each structural class induced the OSM-MEFs to form colonies (Fig. 2B);
however, colonies that stained positive for AP were observed only in the presence of
kenpaullone and lysergic acid ethylamide (data not shown). Kenpaullone proved to be
the most robust reprogramming molecule based on this series of assays and was
studied in more detail.
While AP positive colony formation is consistent with the conversion of somatic to
iPS cells, it does not prove establishment of a pluripotent state. To determine whether
iPS cells derived with kenpaullone were fully reprogrammed, we transduced MEFs
carrying the gene encoding neomycin resistance in the Oct4 locus – ONR-MEF (Wernig
et al., 2007) – with OSM vectors and treated these cells with retrovirally delivered Klf4,
vehicle control or kenpaullone 2 days later (Fig. 2C). Nanog expression was analyzed
by semi-quantitative RT-PCR at three-day intervals to confirm the re-activation
observed using the NL reporter line.  Consistent with observations using NL-MEFs,
Nanog expression was activated in kenpaullone treated OSM-transduced MEFs in a
time dependent manner (Fig. 2C and SI Fig. 2).
After 20 days of concurrent kenpaullone treatment, colonies expressing Oct4 from
their endogenous locus were selected upon supplementation of the culture media with
neomycin (Fig. 2C). Kenpaullone was able to replace Klf4, as demonstrated by the
appearance of Oct4-neo colonies, though reprogramming was less efficient than after
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transduction with a Klf4 vector. Likewise, OSM transduction and kenpaullone treatment
of MEFs carrying a green fluorescent protein (GFP) reporter in the Oct4 locus – O4G-
MEF (Lengner et al., 2007) – gave rise to GFP positive colonies (Fig. 3A) with similar
efficiency and kinetics as observed in the ONR-MEFs (Fig. 3B). DMSO treated OSM-
transduced O4G-MEFs grown did not display GFP positive cells or colony formation
even after >40 days in culture (data not shown).
Characterization of iPS cells. iPS cells generated by OSM and kenpaullone treatment
were indistinguishable from ES cells by morphological criteria and expressed the
pluripotency associated markers Oct4 and Nanog from the endogenous loci (Fig. 3A).
However, the reprogramming efficiency of kenpaullone-treated OSM transduced O4G-
MEFs was 10-fold lower than that of Klf4-infected controls (Fig. 3B). To confirm the
activity of kenpaullone in an independent culture system, we used “secondary” MEFs
that carry doxycycline (DOX)-inducible proviruses encoding Oct4, Sox2 and c-Myc
(Markoulaki et al., 2009). The results shown in Figure 3C indicate that kenpaullone
induces reprogramming of secondary OSM-MEFs with a similar efficiency as primary
infected OSM-MEFs. The reprogramming kinetics of kenpaullone treated iPS cell
formation was, however, delayed as DOX independent iPS cells only appeared after 25-
30 days, rather than after 15 days observed for 4-factor control iPS cells. The slight
kinetic delay in reprogramming suggests that kenpaullone is less efficient in epigenetic
reprogramming than Klf4.
Once established, Klf4-free iPS cells grew in the absence of DOX and kenpaullone
while maintaining ES cell morphology and expression of Nanog and Oct4. To test for
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pluripotency, the cells were injected into blastocysts and found to generate germline
competent chimeras (Fig. 3A and data not shown).
It has been shown that mouse neural progenitor cells (NPC) that express
endogenous Sox2 can be reprogrammed to a pluripotent state with the addition of Oct4
and Klf4 +/- c-Myc (Eminli et al., 2008; Kim et al., 2008b) or simply Oct4 (Kim et al.,
2009), albeit with delayed kinetics and low efficiency. To determine the functionality of
kenpaullone in the reprogramming of neural cells, NPCs were transduced with all
combinations of Oct4, Klf4 and c-Myc and treated with 5 µM kenpaullone or vehicle
control. Eight days later, discernable AP positive colonies had formed in Oct4/c-Myc
kenpaullone-treated wells that, when passaged, appeared morphologically
indistinguishable from ES cells and stained positive for the pluripotency-associated
markers Nanog, Sox2 and AP (Fig. 3D). Furthermore, these cells no longer expressed
GFP from the virally delivered c-Myc vector (pCMV-Myc-IRES-GFP; SI Fig. 3),
consistent with retroviral silencing observed in reprogrammed cells (Wernig et al.,
2007). The efficiency of iPS cell formation from NPCs was lower with kenpaullone than
with Klf4 gene transduction, though not as low as that observed in MEFs (Fig. 3B
versus 3E). It is also worth noting that neither MEFs nor NPCs reprogrammed in the
absence of c-Myc when kenpaullone was substituted for Klf4. Collectively, these results
suggest that kenpaullone requires transduction of c-Myc for reprogramming and
emphasizes that kenpaullone may not completely recapitulate the role of Klf4.
Biological Activity of Kenpaullone. Previous work with kenpaullone has
demonstrated a wide range of biological utility extending from maintenance of
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pancreatic beta cell survival and proliferation (Stukenbrock et al., 2008) to the induction
of apoptosis in cancer cells (Zaharevitz et al., 1999). Kenpaullone’s diverse range of
activity is a direct result of its kinase inhibition promiscuity; i.e., kenpaullone is a potent
inhibitor of GSK-3b (23 nM), CDK1/cyclin B (400 nM), CDK2/cyclin A (680 nM),
CDK5/p35 (850 nM), and exhibits inhibitory activity toward a variety of other kinases at
higher concentrations (Knockaert et al., 2002; Zaharevitz et al., 1999).
To determine if the reprogramming activity of kenpaullone results from its well
established role as a GSK-3β or CDK inhibitor, a highly selective small molecule
inhibitor of GSK-3β (CHIR99021), a promiscuous inhibitor of CDKs (purvalanol A) or
both were applied to OSM-transduced ONR-MEFs and compared against kenpaullone.
As shown in Figure 3F, known inhibitors of these kinases are unable to replace Klf4 in
the reprogramming of murine fibroblasts and have negligible activity in the NL reporter
MEF line (SI Fig. 4).  It is interesting to note that kenpaullone, like CHIR99021,
increases the efficiency of 4-factor reprogramming (Fig. 3F).  This observation is
consistent with reports indicating that GSK-3β inhibitors can facilitate, in part, mouse ES
cell self-renewal (Ying et al., 2008) and the reprogramming of mouse NPCs back to the
pluripotent state (Silva et al., 2008).  However, as other more specific GSK-3β inhibitors
are not able to activate Nanog expression (SI Fig. 4) or to replace Klf4 (Fig. 3F), this
activity is likely independent of the reprogramming activity of kenpaullone.
In addition to small molecule mediated inhibition, short hairpin RNA (shRNA)-
targeted ablation of each of the canonical kenpaullone kinase targets – individually,
combinatorially or in a pooled format – did not result in colony formation or an increase
in Nanog driven luciferase expression in OSM-transduced MEFs (SI Fig. 5).
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Collectively, these data strongly suggest that the activity of kenpaullone does not result
from its well-documented role as a GSK-3β or cell cycle inhibitor.  Lastly, kenpaullone
does not directly activate Klf4 expression at the mRNA or protein level (SI Fig. 6)
suggesting that it is functioning through an entirely novel mechanism.
Discussion
In this work we describe the development and application of an unbiased, high-
throughput (>500K compounds) cell based screening technology that can be applied to
identify small molecules to replace virally transduced reprogramming transcription
factors. In a proof-of-concept application, we have identified three classes of molecules
that activate Nanog expression in murine fibroblasts during direct reprogramming in the
absence of Klf4, and have characterized one such molecule, kenpaullone, in detail. We
showed that kenpaullone is able to replace Klf4 in the reprogramming of primary and
secondary fibroblasts and NPCs. OSM iPS cells derived in the presence of kenpaullone
display the characteristics of pluripotent ES cells, including the ability to contribute to
chimeric mice.
Previous studies with small molecules that induce epigenetic changes suggest that
chromatin remodeling is a rate-limiting step in the conversion from a somatic to a
pluripotent epigenetic state (Huangfu et al., 2008a; Huangfu et al., 2008b; Mikkelsen et
al., 2008; Shi et al., 2008a; Shi et al., 2008b; Wernig et al., 2008a). For example,
treatment of MEFs with a small molecule inhibitor of DNA methyltransferase (5-
azacytidine) facilitates reprogramming during a brief temporal window by removing
demethylation marks, thereby lowering the kinetic barrier to transition to pluripotency
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(Mikkelsen et al., 2008; Wernig et al., 2008a). Furthermore, histone deacetylase
inhibitors and histone methyl transferase inhibitors have also been shown to increase
the efficiency of reprogramming (Huangfu et al., 2008a; Huangfu et al., 2008b; Shi et
al., 2008a; Shi et al., 2008b). In particular, the histone deacetylase inhibitor valproic acid
dramatically increased three-factor reprogramming efficiency in the absence of c-Myc in
both mouse and human cells and enabled two-factor reprogramming (Oct4 and Sox2) of
human fibroblasts in the absence of Klf4 and c-Myc (Huangfu et al., 2008a; Huangfu et
al., 2008b).
While modulation of known epigenetic control elements has provided significant
progress toward reprogramming not requiring genetic manipulations, such techniques
rely on specific compounds to target known mechanisms. As the study of induced
pluripotency is still in its infancy, the mechanisms governing reprogramming remain
largely unknown. It is likely that the activation of different alternative pathways by small
molecules will enhance the efficiency of vector-free reprogramming. Furthermore, the
identification of chemicals with novel mechanisms of action to modulate this process is
of great interest. This work demonstrates that unbiased, cell-based screens can identify
small molecules from large chemical libraries to replace transcription factors for
reprogramming. Moreover, the identification of these and other molecules provide novel
tools to study the molecular mechanisms at play during epigenome overhaul and may
ultimately help to bring iPS cell technology one step closer to clinical application.
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Materials and Methods
Chemicals. Kenpaullone, purvalanol A and 7-hydroxyflavone were purchased from
Sigma, CHIR99021 from Axon MedChem and lysergic acid ethylamide was acquired
from a commercial chemical vendor.  The chemical library was described previously
(Plouffe et al., 2008).
Gene Targeting and Blastocyst Injection. Generation of the Nanog-luciferase
targeting vector is described in detail in the SI methods. For targeting, the Nanog-
luciferase vector was linearized with XhoI and electroporated into ES cells. G418
selection (350 µg/ml) was started 24 hours after electroporation and continued for 10-12
days. Resistant clones were picked and expanded for screening by Southern blot
analysis. Injections of Nanog-luciferase ES or iPS cells into either BDF2 or BALB/C host
blastocysts were carried out as previously reported (Beard et al., 2006).
Cell Culture and Viral Infections. Transgenic MEFs were isolated from Nanog-
luciferase, secondary OSM (Markoulaki et al., 2009), ONR (4) or OGF (Lengner et al.,
2007) mice, selected from E13.5 embryos and cultivated in DMEM (Invitrogen)
containing 15% FBS, L-glutamine, beta-mercaptoethanol and nonessential amino acids.
ES and iPS cells were cultivated on irradiated MEFs in the aforementioned media plus
20 ng/mL LIF (Chemicon).
MEFs at passage 1-2 were infected with pooled viral supernatant generated by
transfection of HEK293T cells (Fugene, Roche) with doxycycline inducible lentiviral
vectors (Brambrink et al., 2008) or the maloney retroviral vectors (pMXs, Addgene;
generously deposited by S. Yamanaka) containing the cDNAs of Oct4, Sox2 and c-Myc
+/- Klf4, and pseudo-typed using with a plasmid encoding the VSV-G envelope protein.
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NPCs were derived from ES cells (Bibel et al., 2007) and expanded 4-5 passages in
DMEM/F-12 (Invitrogen) supplemented with B27 (1X; Invitrogen), EGF (20 ng/mL; R&D
Systems) and FGF-2 (20 ng/mL; Invitrogen). NPCs (105 per well of a 6-well dish) were
infected overnight, followed by transfer to ES cell growth media. For all experiments,
compound(s) or vehicle control (DMSO 0.05%), doxycycline (2 µg/mL) and media were
refreshed every 2-3 days.  The experimental conditions concerning the generation of
iPS cells from NPCs, ONR-, OG4- and secondary-MEFs are described in detail in the SI
Methods section accompanying this paper.
Chemical Screening and Nanog Assay. Nanog luciferase MEFs (~108 cells) were
transduced at passage 1 with concentrated VSV-G pseudotyped Oct4, Sox2 and c-Myc
expressing lentivirus in 15cm dishes. Immunofluorescent staining confirmed that >90%
of NL-MEFs expressed Oct4 (polyclonal mouse, Santa Cruz) and Sox2 (monoclonal
mouse, Santa Cruz).  OSM transduced NL-MEFs were expanded four passages (~2
weeks) prior to screening. For large-scale screens, the OSM NL-MEFs were plated into
1536-well plates at 500 cells/well in mouse ES cell growth media supplemented with LIF
(20 ng/mL). Compounds were added at 2.2 mM final concentration (20 nL of 1 mM
stock solutions in 9 mL of media) immediately after plating. Nanog-driven luciferase
expression was assayed 10 days later by adding 2 µL of Bright-Glo (Promega). Primary
hits were re-screened in triplicate in 1536-well format. Dose response curves were
generated by screening OSM NL-MEFs in 8-pt dilution (1 mM stock, half log serial
dilutions) in 384-well format. ‘Jackknife’ Z score values, the one-sample K-S test value
(P = 0.54) and the empirical and theoretical inverse gamma distribution were calculated
according to Malo, et al. (Malo et al., 2006) and references therein.
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A HEK293T counter-screening cell line was generated by co-transfection of the pGL3
SV40-luciferase vector (Promega, # E1761) with pcDNA3.1+ (Invitrogen, V790-20)
encoding the gene for neomycin resistance.  Neomycin selections (400 µg/mL) were
carried out for 7 days. The SV40-luciferase HEK293T line was passaged in DMEM plus
10% FBS. Hits that reconfirmed in triplicate in NL-MEFs were screened in SV40-luc
293T cells to filter out false positives (Auld et al., 2009).
Counter-screening, dose response experiments, structure and activity relationship
analysis and the timecourse experiments were all run in 384-well plates (Greiner). Cells
were plated at 1K cells/well in ES cell growth media and assayed 10 days later, unless
otherwise specified. All luciferase readings were acquired following addition of Bright-
Glo reagent (Promega). All experiments were run in duplicate and repeated at least
three times.
Semiquantitative RT-PCR Analysis. Total RNA was obtained and reverse transcribed,
as described previously (Lyssiotis et al., 2007).  PCR was performed using the Phusion
polymerase (New England Biosciences) and gene-specific primers (SI Table 4). Cycle
parameters were 10s at 98°C, 15s at 63°C (Nanog) or 67°C (Nat1), and 30s at 72°C for
30 cycles. The amount of total RNA and PCR conditions were optimized so that
amplification of Nat1 and Nanog were in the exponential phase.
Immunocytochemistry and Antibodies. Immunofluorescence analysis was performed
as described previously (Lyssiotis et al., 2007). Antibodies against Sox2 (polyclonal
mouse, Santa Cruz), Oct4 (monoclonal mouse, Santa Cruz) and Nanog (polyclonal
rabbit, Santa Cruz) were incubated with fixed cells, washed and labeled with
fluorophore appropriate secondary antibodies (Jackson Immunoresearch). Alkaline
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phosphatase staining was performed according to the manufacturer’s recommendations
(Millipore). Images were captured using an Eclipse TE2000-U microscope (Nikon) with
_40 or _100 magnification.
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Fig. 1 Nanog luciferase screening platform. (A) Scheme for targeting the firefly (FF)
luciferase gene to the Nanog locus. (B) Southern blot hybridization analysis of the
Nanog-luciferase targeted allele. The targeted allele-specific 5.2kb and 4.7 kb PvuII
fragments are detected with the 5’ internal and 3’ external probes, respectively, shown
in A. (C) Nanog-luciferase activity of correctly targeted ES cell clones (NL2 and NL5)
versus Nanog-luciferase MEFs. Differentiated Nanog-luciferase tissue shows a
significant reduction in luciferase expression. V6.5 ES cells and MEFs are provided as a
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luciferase negative control. (D) Small molecule screening strategy. Nanog-luciferase
MEFs were transduced with a reduced reprogramming cocktail (Oct4, Sox2 and c-Myc;
OSM), expanded for 2 weeks, plated into 1536-well plates, treated with compound and
assayed for luciferase expression 10 days after plating. The initial library of 500,000
compounds was narrowed down to ~1,000 compounds that reproducibly activated the
Nanog reporter, 135 of which were confirmed in dose-response format. Representative
members of each chemical class activated the Nanog reporter approximately 3-fold over
untreated OSM-MEFs and near equivalent to that observed in pluripotent cells.
Flavones (7-hydroxyflavone, 20 µM), Ergolines (lysergic acid ethylamide, 2 µM) and
Paullones (kenpaullone, 5 µM). Nanog activity is reported in RLU and was read in 96-
(B) or 384- (D) well format. Error bars for all experiments represent the standard
deviation (n = 3).
Fig. 2 Activity of lead chemical scaffolds. (A) Dose-dependent Nanog activation of a
lead compound from each chemical class: lysergic acid ethylamide (Ergolines), 7-
hydroxyflavone (Flavones), kenpaullone (Paullones). Above 10 µM, kenpaullone and
lysergic acid ethylamide are toxic. (B) OSM-MEFs took on colony morphology upon
application lead compounds. i – DMSO; ii – KLF4; iii, 7-hydroxyflavone, 20 µM; iv,
lysergic acid ethylamide; 2 µM; v, kenpaullone, 5 µM. (C) ONR-MEFs were transduced
with OSM (day -2) and treated with DMSO, retrovirally-delivered Klf4 or kenpaullone 2
days later (day 0). Semi-quantitative RT-PCR of samples collected at days 3, 6, 9 and
12 confirmed the re-activation of Nanog observed using NL-MEFs. At day 20,
kenpaullone and DMSO were removed, and neomycin was added to the culture media
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to initiate selection of iPS cells. Neomycin-resistant colonies – indicating re-activation of
endogenous Oct4 – were counted at day 25 (per fifty thousand MEFs). Error bars,
standard deviation (n = 4 wells of a 6-well plate). Dose response curves are
representative of at least 6 independent experiments and were read in 384-well format.
Images were captured at _40 magnification.
Fig. 3 Characterization of iPS cells derived with kenpaullone. (A) iPS cells generated
with OSM and 5 µM kenpaullone express the pluripotency associated markers Oct4 and
Nanog from their endogenous loci and are capable of contributing to chimeric mice. (B)
Chemical complementation of Klf4 with kenpaullone is less efficient than retroviral
delivery of Klf4, as scored by the number of colonies (per ten thousand MEFs) that
express GFP from the endogenous Oct4 locus. Error bars, standard deviation (n = 3).
(C) Secondary MEFs harboring proviral copies of OSM were treated with kenpaullone (5
µM) or retrovirally delivered Klf4. Colonies were scored based on expression of OCT4.
(D) Kenpaullone-treated Oct4/c-Myc-NPCs gave rise to iPS cells that expressed
pluripotency associated proteins (Nanog, Sox2 and AP) from endogenous loci. (E)
NPCs were transduced with Oct4 +/- Klf4 and c-Myc and treated with kenpaullone (5
µM) or vehicle control. Data represent colonies that expressed AP after 8 days (per one
hundred thousand NPCs). Error bars, standard deviation (n = 3). (F) ONR-MEFs were
transduced with OSM +/- Klf4 and treated with a GSK-3β specific inhibitor (GSKi;
CHIR99021, 3 µM), a general CDK inhibitor (CDKi; purvalanol A, 3 µM), both the GSKi
and the CDKi, or kenpaullone. Colonies were scored for neomycin-resistance at day 25
(per fifty thousand MEFs). Error bars, standard deviation (n = 4).
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Chapter 6
Perspectives
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Embryonic stem cells have significant therapeutic potential for use in
regenerative medicine given their pluripotency, or their ability to differentiate into
tissues of all three germ layers. Nuclear reprogramming of somatic cells offers
the possibility of generating patient-specific stem cell lines, removing some of the
obstacles hindering the therapeutic use of ES cells, including the need for
immunosuppression after tissue transplants. A breakthrough in the field of
reprogramming occurred when Takahashi and Yamanaka reported that retroviral
transduction of the four transcription factors Oct4, Sox2, Klf4 and c-Myc induces
a pluripotent state in somatic cells, generating iPS (induced pluripotent stem)
cells (Takahashi and Yamanaka, 2006). The work in this thesis focuses on
reprogramming using these defined factors.
Takahashi and Yamanaka’s initial study did not generate fully reprogrammed iPS
cells, but subsequent work, including that detailed in Chapter 2, describes the
use of more stringent selection markers Oct4 and Nanog to isolate fully
reprogramming iPS cells from four-factor-transduced fibroblasts. Once it was
established that viral transduction of the four reprogramming factors indeed
induced a pluripotent state in somatic cells, we began to explore the mechanism
underlying nuclear reprogramming, providing an analysis of the re-activation
kinetics of key pluripotency markers. We found, as detailed in Chapter 3, that
reprogramming events occur gradually and sequentially over time. Using
doxycycline-inducible viruses, this study also identified a minimum time
requirement for transgene expression during the reprogramming process. This
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timeline was then used as a benchmark for subsequent reprogramming
experiments.
One main obstacle to realizing the therapeutic potential of iPS cells is the current
reliance on viral transduction of the reprogramming factors and the multiple
genomic integration sites iPS cells can contain. Not only can integrated viruses
activate endogenous genes, including oncogenes, but reactivation of the viral
transgenes can also occur. Roughly 50% of chimeric mice generated from iPS
cells were prone to tumorigenesis due to c-Myc re-activation (Okita et al., 2007).
Recent studies have begun to address viral integrations in reprogramming. One
group was able to reprogram hepatocytes using non-integrating adenoviral
vectors encoding the reprogramming factors, while another used transient
transfection of a plasmid containing Oct4, Sox2 and Klf4 in a single expression
vector (Okita et al., 2008; Stadtfeld et al., 2008). While iPS cells from both
studies contain no viral integrants, reprogramming was highly inefficient,
hindering its widespread use. More recently iPS cells were generated by
genomic integration of the four reprogramming factors using plasmids,
lentiviruses, or transposons, followed by excision of the viral transgenes using
Cre-recombinase or transposase expression (Kaji et al., 2009; Soldner et al.,
2009; Woltjen et al., 2009). While the majority of the transgene is excised in
these studies, small portions still remain in the iPS cells, which could cause
safety concerns if they are used for therapeutic purposes.
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The ability to identify viral alternatives remains a key focus of scientific research.
Work in this thesis, specifically in Chapters 4 and 5, details the identification of
transient cues as replacements for the viral reprogramming factors. One method
employed a candidate approach, applying the knowledge that Wnt signaling
feeds into the core regulatory circuitry of ES cells (Cole et al., 2008). We show in
Chapter 4 that stimulation of the Wnt pathway can promote iPS cell formation in
the absence of c-Myc. In addition to a candidate approach, we developed a high-
throughput chemical screening platform described in Chapter 5 to identify small
molecules that replace the viral factors essential to reprogramming. One
compound in particular, Kenpaullone (Kp), was identified that functionally
replaces Klf4. This screening platform could be extrapolated and used to isolate
replacements for the other reprogramming factors. High-throughput screening
also offers the possibility of identifying novel compounds that provide mechanistic
insight into the process of reprogramming, which is poorly understood.
The identification of chemical combinations that can achieve reprogramming in
somatic cells may require sequential rounds of screening, using the previously
identified compounds in the subsequent screening steps, rather than simply
combining compounds identified from two independent experiments. This is
highlighted in our work with the compound Kp. Although c-Myc has been shown
to be dispensible for reprogramming in the presence of Oct4, Sox2 and Klf4
(Nakagawa et al., 2008; Wernig et al., 2008b), the replacement of Klf4 with Kp
was dependent on c-Myc. Furthermore, the combination of Kp and Wnt3a was
170
unable to replace viral Klf4 and c-Myc, although independently they can replace
the viral factors. Sequential high-throughput screening could also be combined
with a low-throughput, candidate approach to comprehensively identify
combinations of compounds that could be used to reprogram somatic cells.
Chemical compounds could also be used to improve the efficiency of
reprogramming, which becomes more critical as we replace the viral
reprogramming factors with less efficient alternatives.
Published chemical screens to date have used primary infected cells to screen
for compounds. Inherent in the use of primary infected cells is the genetic
heterogeneity of the transduced cell population and the repeated need for high
titers of retroviruses. One solution to the heterogeneity of transduced cell
populations is the use of “secondary” cells. “Secondary” cells carry doxycycline-
inducible proviruses that do not require new virus infection to induce
reprogramming and can reprogram with higher efficiency than primary infected
cells (Wernig et al., 2008a). More recently, improved secondary lines were
isolated with single proviral copies of the reprogramming factors (Markoulaki et
al., 2009). Some of these lines were missing one or more of the four transcription
factors and were able to reprogram only if the missing factor(s) was virally
transduced. These secondary lines would be ideal for use in a chemical screen
to identify small molecules to replace the reprogramming transcription factors.
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Inherent in the generation of chemically reprogrammed cells is the careful
examination that chemical treatment does not cause genetic abnormalities or
genomic instability in the resulting iPS cells. Genomic sequencing is one way in
which this could be achieved, especially in cells used therapeutically. An
additional method that could be used to replace viral reprogramming is transient
protein transfection of the reprogramming factors. A recent publication details the
generation of iPS cells using media supplemented with engineered proteins that
penetrate the cell membrane of somatic cells and translocate to the nuclei (Zhou
et al., 2009). While this method was highly inefficient and could only reprogram
cells in the presence of the chemical valproic acid, it represents a viable
alternative to viral reprogramming and one that does not introduce any genetic
material into the somatic cells.
Although iPS cells could be used therapeutically as a donor source for cell
transplantation, the ability to isolate patient-specific iPS lines opens new
possibilities for human disease models (Dimos et al., 2008; Park et al., 2008;
Soldner et al., 2009). The in vitro differentiation of patient-specific iPS cells offers
the opportunity to model human disease with the exact genetic mutations that
cause that disease rather than using mouse models, which can be artificial
representations of disease processes. Inherent in their use in in vitro modeling
systems, is the ability to differentiate iPS cells into multiple tissue lineages. This
is another area where chemical screening platforms can identify molecules that
will drive stem cell differentiation down specific developmental pathways. Not
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only will this be important for in vitro modeling of diseases, but also in the
differentiation of iPS cells for tissue transplantation and regenerative therapy.
I have discussed the use of chemical screens to isolate compounds to replace
the reprogramming transcription factors, but one use of iPS cells could be in
therapeutic drug testing (Rubin, 2008). Patient-specific iPS cells could be in vitro
differentiated into the cell type affected by a particular disease and drug screens
could then be performed to identify pharmaceuticals that alleviate specific cellular
defects caused by that disease. Furthermore, iPS cells could revolutionize
toxicity testing of pharmaceuticals. Rather than first identifying toxic side effects
in clinical trials, an in vitro panel of tissue types, including hepatocytes,
differentiatied from iPS cells could be analyzed before Phase I clinical trials.
These examples suggest that the true benefit of iPS cells to human disease may
be as an investigative, laboratory tool rather than as a direct source of
transplantable tissue.
While reprogramming to a pluripotent state has broad clinical applications, the
ability to convert one somatic cell type to another without going through a
pluripotent intermediate, or “transdifferentiation,” also has therapeutic potential.
By not going through a pluripotent intermediate, “transdifferentiated” cells may be
less likely to form teratomas upon tissue transplantation and may therefore be
more desirable to use therapeutically. A recent study on the transcription factor-
induced reprogramming of pancreatic exocrine, acinar cells to endocrine, insulin-
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producing β cells is an important advance in the understanding and feasibility of
“transdifferentiation” (Zhou et al., 2008). It remains to be seen whether any cell
type can be derived from a skin cell or whether there are epigenetic barriers to
crossing germ layers or cell lineages. A more detailed knowledge of cellular
signaling programs and transcription factor-induced cell fate changes will inform
the future study of transdifferentiation.
In summary, the induction of pluripotency by defined transcription factors has
broadened the field of stem cell research. The work in this thesis focused on the
process of reprogramming, its mechanisms and how to make it therapeutically
applicable. We are just beginning to understand the reprogramming process and
the multitude of applications for which it can be used. We stand at the forefront of
a new era in the understanding not only of pluripotency, but of human disease
processes and the determination of cellular fate.
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Figure S1:  In Vitro Characterization of a Nanog-neo iPS cell line (clone 8). Nanog-
neo resistant colonies closely resembling ES cells were selected to establish iPS 
cell lines. Nanog-neo iPS clone 8 grew as ES cell-like colonies on irradiated MEFs 
(A), was labeled homogenously with antibodies against SSEA1 (B, DAPI in C). 
Most colonies had a strong alkaline phosphatase activity (D) and a large fraction 
of the cells contained nuclear Nanog protein (E), DAPI (F).
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Figure S2: “Bivalent domains” in Nanog-neo iPS clone 8 (A) and subclone 18.1 
of Oct4-neo iPS clone 18 (B). Shown are the log2 enrichments of chromatin 
immunoprecipitated material with antibodies specific for tri-methylated histone 
H3K4 and H3K27 as detected by quantitative RT-PCR. Green bars represent the 
“active” H3K4 mark, yellow bars the “repressive” H3K27 mark.
Figure S3 Multilineage differentiation of Oct4-neo iPS cells following injection 
into SCID mice. Sixteen to 26 days after subcutaneous injection of iPS cells 
resulting tumors were fixed, embedded in paraffin, sectioned and stained 
with Hematoxylin and Eosin. Somatic cell types found included proliferative 
neuroectoderm (A), mature central nervous system (CNS) tissue (B), 
keratinizing squamous epithelia (C), cartilage (D), cuboidal epithelia containing 
goblet cells (E) and ciliated cuboidal epithelia (F).
Figure S2 Figure S3
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Figure S4:  Immunohistochemical characterization of teratomas. A)  Postmitotic 
neurons within a neural tube-like structure were labeled with antibodies against 
beta-III-tubulin, B) Glial fibrillary acidic protein (GFAP)-positive astrocytes in 
another part of the tumor resembling mature CNS tissue C) Desmin-positive 
striated muscle-fibers, D) Smooth muscle actin (SMA) expressing cells) E) 
Cytokeratin expression in epidermis-like epithelial cells, F) GATA4-positive 
endothelium.
Figure S5: Characterization of tailtip fibroblast-derived iPS cells. iPS cell lines 
were established from tailtip fibroblasts utilizing Nanog or Oct4 selection. A-
D) In vitro characterization of Oct4-iPS clone TT-O16 displaying ES cell-like 
morphology (A), homogenous staining for SSEA1 (B, corresponding DAPI 
image B’), alkaline phosphatase (C), Nanog (D, corresponding DAPI image D’). 
Oct4-iPS Clone TT-O25 was injected into diploid blastocysts resulting in high 
contribution mid-gestation embryos (E bright field, E’ EGFP fluorescence).
cell line karyotype (20 cells analyzed per cell line) 
O3-2 40, XY (20) 
O9 40, XY (16); 39, X0 (1); various losses or gains of other chromosomes (3) 
O18 41, XY+12 (17); 42, XY+10+12 (3) 
N8 40, XY (19); 39, X0 (1) 
N14.2 40, XY (20) 
Figure S4 Figure S5
Table S1
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Appendix B: Supplemental Material for Chapter 3
Sequential expression of pluripotency markers during direct
reprogramming of mouse somatic cells
Tobias Brambrink, Ruth Foreman, G. Grant Welstead, Christopher J. Lengner,
Marius Wernig, Heikyung Suh and Rudolf Jaenisch
Figure S1: Quantitative RT-PCR assays of viral trangene expression in
infected MEFs.
MEFs were infected and grown in the absence or the presence of dox. Average
relative expression levels and standard deviations from two RT-PCR reactions
are shown for all four factors. ES cell values are given as a positive control.
Figure S2: FACS analyses of AP, SSEA1 and GFP expression in infected
MEFs and control ES cells.
FACS analysis of AP, SSEA1 and GFP reactivation was performed on
NanogGFP/M2rtTA MEFs and Oct4GFP/M2rtTA MEFs at different times after the
induction of reprogramming. Cells were harvested at various time points after the
addition of dox to the medium and stained with an APC labeled anti-SSEA1
antibody and a fluorescent substrate detecting AP activity. Representative FACS
plots of three independent experiments are shown. The fraction of AP positive
cells increases with time after transgene induction. In the histogram plots of AP
staining, the red line represents the negative control (infected MEFs cultured
without dox) and the solid purple represents induced MEFs analyzed at the
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specified time (A). The numbers displayed for each plot are the number of cells in
the M1 gate which was set so that less than 1% of cells in the negative control
were in the M1 population. Analysis of SSEA1 and GFP expression (B). Dot plots
of GFP and SSEA1 signals are displayed and the percentages of cells for the
SSEA1+/GFP- and the SSEA1+/GFP+ populations are shown.  AP positive cells
were first observed on day 3, while SSEA1 positive cells appeared on Day 9.
Cells positive for Nanog-GFP or Oct4-GFP were first detected on day 16 and
most of these cells also stained positive for SSEA1.
Figure S3: Morphology of non-reprogrammed cell colonies.
Pictures of cell colonies on induced plates at the time specified (A). Plates were
re-assessed at day 35 of the experiment and pictures of cell colonies that were
detectable are shown (B).
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Appendix C: Supplemental Data for Chapter 4
Wnt signaling promotes reprogramming of somatic cells to pluripotency
Alexander Marson, Ruth Foreman, Brett Chevalier, Steve Bilodeau, Michael
Kahn, Richard A. Young, and Rudolf Jaenisch
Supplemental Experimental Procedures
Mice, cell lines, retroviral vectors, cell culture, flow cytometry, immunostainings,
teratoma formation and blastocyst injections were previously described in detail
(Wernig et al., 2007; Meissner et al., 2007; Brambrink et al., 2008). Wnt3a
conditioned media (Willert et al., 2003) and control conditioned media from
parental L cells were generated according to standard protocols (ATCC), and
used in a 1:1 dilution with standard ES cell medium. It has been previously
shown that the conditioned media from Wnt3a-overexpressing cells has Wnt
signaling activity as determined by TOP flash assays (Ogawa et al., 2006) and
that functional Wnt3a protein can be purified from this media (Willert et al., 2003).
Furthermore, secretion of Wnt3a protein can be detected by immunoblot of the
conditioned media from Wnt3a-overexpressing cells (Shibamoto et al., 1998).
ICG-001 was dissolved in DMSO to a stock concentration of 0.1M and used at a
final, working concentration of 4uM (or as indicated in Supplemental Figure S2).
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Cell Line Injected
Blastocysts
Live
Chimeras/Live
Births
Germline Transmission
KSOW49 21 1/2 Yes
KSOW52 37 1/7 Yes
Supplemental Table S1. Two clonal cell lines (KSOW49 and KSOW52) derived
from Oct4-GFP MEFS overexpressing Oct4/Sox2/Klf4 in the presence of Wnt3a-
CM were injected into blastocysts. Total number of blastocysts, live births and
live births with chimeric contribution from iPS cells (as determined by coat color)
are shown. Both lines were competent to contribute to the germline of chimeric
mice (shown here in and in Figures 1E and 1F).
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Supplemental Figure S1 Gsk3 inhibitors and reprogramming in the absence
of c-Myc retrovirus. a. MEFs with doxycycline (DOX)-inducible Oct4/Sox2/Klf4
were cultured in ES cell medium (ES), ES cell medium supplemented with the
glycogen synthase kinase-3 (Gsk-3) inhibitor 6-bromoindirubin-3'-oxime
(BIO,Sigma), or Wnt3a over-expressing conditioned media (Wnt3a-CM). G418
selection was initiated on Day 5 (gray bars) or Day 10 (black bars) post-
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doxycycline induction as indicated. Counts are shown for G418-resistant
colonies. b. MEFs with doxycycline (DOX)-inducible Oct4/Sox2/Klf4 were
cultured in ES cell medium (ES), ES cell medium supplemented with the Gsk-3
inhibitor CHIR99021 (Ying et al., 2008), or Wnt3a over-expressing conditioned
media (Wnt3a-CM). Mean number of G418-resistant colony counts from triplicate
experiments is displayed with error bars indicating S.D. Although neither BIO nor
CHIR99021 promoted reprogramming in these experiments, these small
molecules could prove useful at different doses or in combination with other
chemicals.
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Supplemental Figure S2 Effect of ICG-001 on reprogramming with four
factor-induced MEFs. MEFs with doxycycline (DOX)-inducible
Oct4/Sox2/Klf4/c-Myc were cultured in Wnt3a over-expressing conditioned media
(Wnt3a-CM) with 4µM, 10µM or 25µM ICG-001. G418 selection was initiated on
Day 15 post-doxycycline induction. Counts (in a 32cm2 area) are shown for
G418-resistant colonies. Mean number of G418-resistant counts from triplicate
experiments is displayed with error bars indicating S.D. Because G418-resistant
colonies on one plate of cells treated with Wnt3a-CM and 4µM ICG-001 were too
dense to count, data shown for this concentration of ICG-001 only reflect with
mean of duplicate data.
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Supplemental Figure S3 Absence of endogenous Myc induction with
Wnt3a-CM treatment. Quantitative RT-PCR analysis of RNA extracted (RNeasy,
Qiagen) from Oct4-inducible, Oct4-G418 selectable cells transduced with Klf4
and Sox2. Cells were either treated with doxycycline (DOX), or doxycycline and
Wnt3a-CM (WNT), as indicated. Transcript levels, assessed with Taqman probes
(Applied Biosystems), were normalized to Gapdh levels. Values are reported as
fold-change relative to cells not treated with DOX or WNT. Error bars indicate
standard deviation derived from triplicate PCR reactions. No Wnt-dependent
activation of c-Myc was observed in the population of cells examined. However,
191
we cannot exclude that Wnt3a enhances c-Myc expression in the rare cells that
will eventually become iPS  cells.
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Appendix D: Supplemental Data for Chapter 5
Reprogramming of murine fibroblasts to iPS cells: Chemical
Complementation of Klf4
Costas A. Lyssiotis, Ruth K. Foreman, Judith Staerk, Michael Garcia, Divya
Mathur, Styliani Markoulaki, Jacob Hanna, Luke L. Lairson, Bradley D. Charette,
Laure C. Bouchez, Michael Bollong, Conrad Kunick, Achim Brinker, Charles Cho,
Peter G. Schultz and Rudolf Jaenisch
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1Supplemental Text
Structure and activity relationship (SAR) analysis of a 100 member paullone
collection (1, 2) in the Nanog-luciferase assay demonstrated that the core paullone
scaffold is sensitive to modification and that kenpaullone is the most active member (SI
Fig. 5 and SI Table 1). Interestingly, however, a variety of analogs that have no kinase
inhibitory activity against canonical kenpaullone kinase targets (i.e., CDK1, CDK5, GSK-
3β) were still active in the Nanog reporter assay (SI Fig. 5).  One analog (Kun152) that
was active in the Nanog assay (2.4-fold relative to DMSO-treated controls), ineffectual
toward the canonical paullone kinases (>10 µM) and did not activate Wnt signaling (SI
Fig. 5F) was selected for further kinase profiling. Kun152 demonstrated negligible
activity against a 57 member tyrosine kinase profile at 5 µM in vitro (SI Table 2),
suggesting that it is not a non-selective kinase inhibitor.  Collectively these data,
together with the data Figure 3F and SI Figure 4, suggest that the Nanog activating
ability of the paullone scaffold does not result from inhibition of the canonical kinase
targets nor via general tyrosine kinase inhibition.
Supplemental Methods
Characterization of kenpaullone (3). 9-Bromo-7,12-dihydro-indolo[3,2-
d][1]benzazepin-6(5H)-one, colorless crystalline solid, C16H11BrN2O. Purity of purchased
compound was checked by NMR and MS respectively. 1H NMR (400MHz, DMSO-d6): _
= 11.81 (br.s, 1H, NH), 10.13 (br.s, 1H, NH), 7.92 (d, J = 2.0 Hz, 1H), 7.73 (dd, J = 8.2,
1.4 Hz, 1H), 7.42-7.37 (m, 2H), 7.32-7.24 (m, 3H), 3.35 (s, 2H). 13C NMR (100MHz,
DMSO-d6): _ = 171.4, 136.0, 135.6, 134.0, 128.5, 128.4, 128.3, 127.0, 124.5, 123.7,
122.3, 120.4, 113.4, 111.7, 107.2, 31.3. MS (EI): m/z: 327, 328, 329, 349, 351.
Chemicals. Synthesis of the 100 member paullone collection was described previously
(2, 4, 5).  CDK and GSK-3β inhibitors were purchased from Calbiochem with the
exception of kenpaullone and purvalanol A, which were purchased from Sigma and
CHIR99021 (Axon MedChem).
Gene Targeting and Blastocyst Injection. The Nanog-luciferase targeting vector was
generated by first subcloning a PGK-neomycin cassette flanked by 2 loxP sites into a
pSP72 vector with BamHI and XhoI. The 5’ targeting arm was inserted into this BamHI
site and a ClaI site in the pSP72 vector. The 5’ arm spanned 1188bp of the Nanog
promoter and was flanked by a ClaI site at the 5’ end and a BamHI site at the 3’ end.
These restriction sites were added to the PCR primers that were used to amplify the 5’
arm from a BAC containing this region of the Nanog promoter. The primers for PCR of
the 5’ arm were as follows: Forward (ATCGATCTGGGTTAGAGTGTCTTTCACTCAC)
and Reverse (GGATCCGTCAGTGTGATGGCGAGGGAAGGG). The 3’ arm spanned
1.4kb of Nanog intron 2 and was amplified from a BAC using the following PCR primers:
Forward (GCGGCCGCGTAAGGAATTCAGTCCCCGAA) and Reverse
(GCGGCCGCCTCGAGGCCCTCTTCTGGAGTGTCTGAAGAC). The 3’arm was cloned
into the XhoI site of the vector. A 1.9kb NcoI/BamHI fragment of pGL3-basic (Promega)
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2containing the firefly luciferase gene and a SV40 pA signal was blunt-end ligated into
the vector.
For targeting, the Nanog-luciferase vector was linearized with XhoI and
electroporated into ES cells. G418 selection (350 µg/ml) was started 24 hours after
electroporation and continued for 10-12 days. Resistant clones were picked and
expanded for screening by Southern blot analysis. DNA from resistant clones was
digested with PvuII and run on a 0.8% agarose gel. 3’ end homologous recombination
was examined by a 415bp external probe that was PCR-amplified from Nanog intron 2
using primers: Forward (GCTACCTGAGACCCTATCCCTTAG) and Reverse
(CATCTCACCAGCCCTACATACAGTG). This 3’ external probe identified the Nanog
wild-type allele 6.4kb PvuII fragment and the Nanog-luciferase targeted allele 4.7kb
PvuII fragment. 5’ end homologous recombination of resistant clones was analyzed
using a 340bp XbaI/HindIII fragment of the Nanog-luciferase targeting vector. This
internal probe identified a wild-type 6.4kb PvuII fragment and a targeted 5.2kb PvuII
fragment.
Cell Culture and Viral Infections. ONR-MEFs (at passage 1-2; 5 _ 104 cells/well of a
6-well dish) were infected overnight with concentrated viral supernatant.  Virus was
generated by transfection (FugeneHD, Roche) of GP2-293 packaging cells (Clontech)
with moloney based retroviral vector pMXs containing the cDNA of Oct4, Sox2 and c-
Myc +/-Klf4 (Addgene, deposited by S. Yamanaka) together with the VSV-G packaging
plasmid. Media and compound (or vehicle control; DMSO 0.05%) were changed every
2-3 days.  At day 20, selection was initiated by adding G418 (300 µg/mL) to the culture
media.  Colonies were counted – based on survival – or passaged onto irradiated MEFs
in ES cell growth media at day 25.
OG4-MEFs (at passage 1-2; 104 cells/well of a 6-well) were infected with pooled viral
supernatant generated by transfection of HEK293T cells (Fugene, Roche) with
doxycycline inducible lentiviral vectors (6) containing the cDNAs of Oct4, Sox2 and c-
Myc +/- Klf4, together with a plasmid encoding the VSV-G envelope protein.  Media was
supplemented the following day with doxycycline (2 µg/mL) and kenpaullone or DMSO.
Green colonies were selected two weeks later and expanded under ES cell growth
conditions.
NPCs (at passage 4-5; 105 cells/well of a 6-well dish) were infected overnight with
concentrated viral supernatant generated with the following plasmids; pMXs-Oct4 +/-
pMXs-Klf4 and pCIGAR-Myc (an MSCV-based, bicistronic retroviral vector modified to
permit Gateway-mediated insertional recombination of full-length or ORF transgenes
immediately upstream of an IRES-eGFP marker). Compounds were added 12 hours
later and changed every two days thereafter.  At day 8, colonies were either fixed and
stained for AP or passaged onto irradiated MEFs in ES cell growth media.
Colony forming assays with secondary OSM-MEFs were performed as described
previously (7) and analyzed for Oct4 expression 25 days later.
Timecourse Analysis. OSM-transduced NL-MEFs were plated at 1K cells/well in ES
cell growth media, treated with kenpaullone (5 µM) and assayed at the indicated time
points. All luciferase readings were acquired following addition of Bright-Glo reagent
(Promega). Cell number was normalized at each time point by assaying parallel plates
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3for total ATP levels using the cell titer-glo reagent (Promega). The assay was run in
384-well plates (Greiner).
Quantitative and Semi-Quantitative RT-PCR. Total RNA was obtained and reverse
transcribed, as described previously (8).  TaqMan real-time PCR was performed using
the TaqMan Gene Expression Master Mix (Applied Biosystem) and ABI Prism 7900HT
fast real time PCR system with Klf4 probes (Applied Biosystems: Mm00516105_g1,
MGB probe) and normalized to GAPDH (4326317E, VIC probe) as endogenous
controls.
For semi-quantitative analyses, PCR was performed using the Phusion polymerase
(New England Biosciences) and gene-specific primers (SI Table 4). Cycle parameters
were 10s at 98°C, 15s at 51°C (CDK1), 54°C (CDK2), 63°C (GSK-3β), 61°C (CDK5) or
67°C (Nat1), and 30s at 72°C for 30 cycles. The amount of total RNA and PCR
conditions were optimized so that amplification of both Nat1 and the cDNAs of interest
were in the exponential phase.
Western Blotting. Protein extraction, preparation, gel electrophoresis and transfer were
performed as described previously (9). Membranes were blocked (5% non-fat dry milk
in Tris buffered saline with 0.5% Tween-20 ), washed and incubated with primary
antibodies (Klf4, Santa Cruz; γ-tubulin, Sigma; β-actin, )  in blocking solution for 2 hr at
room temperature or 4˚C overnight, washed and incubated with the corresponding
horse radish peroxidase-conjugated secondary antibodies at room temperature for 1 hr.
Finally, membranes were washed and subjected to enhanced chemi-luminescence
detection.
Short-Hairpin Knock-downs. Lentiviral particles containing short hairpin (sh)RNAs
were generated by transfecting HEK293T cells (FugeneHD, Roche) with pooled pLL3.7
vectors encoding the desired knock-down (SI Table 5), packaging vectors and VSV-G.
72 hours later, viral supernatant was collected, concentrated (Amicon) and applied to
OSM-transduced NL-MEFs.  Individual cell lines were made for each kinase knock-
down.  2 days later, cells were sorted for pLL3.7-driven GFP; flow cytometric analysis
indicated that infectivity was >90%.  Combinatorial knock-down was achieved by
treating single knock-down lines with lentiviral particles targeting additional kinases.
ONR-MEFs at passage 1-2 were infected with pooled viral supernatant containing
shRNAs targeting CDK1, CDK2, CDK5 and GSK-3β.  2 weeks later, cells were fixed
and AP stained.
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4SI Fig. 1 Nanog-luciferase validation assay. OSM-transduced NL-MEFs were treated
with a known drug compound plate in 1536-well format and analyzed 10 days later for
luciferase activity; values represent the mean of three independent runs. Nanog activity
is reported in relative light units (RLU).
SI Fig. 2 Timecourse of Nanog activation.  OSM-transduced NL-MEFs were treated with
kenpaullone (5 µM) or DMSO (0.05%) and analyzed for luciferase activity as a function
of time. Nanog expression is reported in RLU and is normalized for cell number
(obtained via analysis of ATP concentration; read in parallel plates).  Error bars,
standard deviation (n=3).
SI Fig. 3 Retroviral vectors are silenced in iPS cells derived from NPCs with Oct4/c-Myc
and kenpaullone. NPCs were transduced with Oct4 and a c-Myc vector harboring an
IRES-GFP cassette.  (A) After eight days of kenpaullone treatment (5 µM), definitive
colonies (B) expressing GFP were visible.  (C) Colonies passaged under mouse ES cell
conditions resembled murine ES cells morphologically and (D) did not express GFP,
consistent with the silencing of retroviral elements observed in reprogrammed cells.
SI Fig. 4 Dual inhibition of CDKs and GSK-3β fail to recapitulate the activity of
kenpaullone. (A) OSM-transduced NL-MEFs were treated in a dose dependent fashion
with CDK or (B) GSK-3β inhibitors in 384-well format and analyzed for luciferase activity
10 days later. (C) OSM-transduced NL-MEFs were plated in screening media containing
a potent, selective GSK-3β inhibitor (CHIR99021, 3 µM) or (D) a general CDK inhibitor
(purvalanol A, 3 µM) and treated in a dose dependent manner with CDK or GSK-3β
inhibitors, respectively. 10 days after treatment, the cells were analyzed for luciferase
expression.  Data points represent the mean of triplicate runs and are representative of
at least 3 independent experiments.  Values that drop off sharply at high concentration
indicate cellular toxicity.  Kinase inhibition data are presented in SI Table 3.
SI Fig. 5 Paullone induced activation of Nanog activity does not result from inhibition of
the canonical paullone kinase targets. (A) Paullone scaffold. Atom labeling corresponds
to the SAR data in SI Table 1. (B) Structure of kenpaullone and the paullone analog,
Kun152, profiled for kinase activity. Kinase inhibition data is detailed in SI Table 2. (C)
Plots of Nanog activity versus inhibition of CDK1, (D) CDK5 or (E) GSK-3_. Each point
on the graph represents a different member of the paullone collection. Kenpaullone is
depicted in red.  Kinase inhibition data was obtained previously (1), and is plotted as the
IC50 value in µM. (F) Nanog activity was plotted against TCF/LEF-driven luciferase
activity – representative of GSK-3β inhibition (10) – for the 100-member paullone library.
Kun152 is depicted in orange. (G) OSM-transduced NL-MEFs were treated with
lentiviral particles containing short hairpin (sh)RNAs targeting the canonical paullone
kinase targets, either individually or combinatorially, and analyzed for luciferase
expression 10 days later. Kenpaullone (5µM) was included as a positive control. (H)
Lentiviral particles containing shRNAs targeting Cdk1, Cdk2, Cdk5 and Gsk-3_ were
pooled and applied to OSM-MEFs. Cells were AP stained two weeks later. Klf4 and
kenpaullone (5µM) were included as positive controls. (I) RT-PCR analysis of OSM-
197
5transduced NL-MEFs for the indicated knock-down(s). Data points presented in A-D
represent the mean of triplicate runs and are representative of at least 3 independent
experiments.  Nanog and Wnt activity for the paullone analogs were plotted at the most
active, non-toxic compound concentration. Error bars in G, standard deviation (n=5).
SI Fig. 6 Klf4 is not activated by kenpaullone. (A) OSM-transduced MEFs were treated
with DMSO, retrovirally-delivered Klf4 or kenpaullone (5 µM).  Klf4 expression was
analyzed at 3 day intervals by quantitative RT-PCR and normalized to GAPDH.  Error
bars, standard deviation (n=3). (B) Secondary MEFs that carry doxycycline (DOX)-
inducible proviruses encoding Oct4, Sox2 and c-Myc (7) were treated with kenpaullone
(5 µM) or vehicle control and western blotted for Klf4 expression at days 4 and 7. (C)
Secondary MEFs carrying a DOX-inducible proviral copy of Klf4 (TetO-Klf4) were
treated with kenpaullone (5 M), vehicle control or DOX (positive control).  Wild type (wt)
MEFs were treated with kenpaullone (5 µM), a GSK-3β specific inhibitor (CHIR99021, 3
µM) or vehicle control.  Samples were analyzed by western blot 92 hours later.  Data
are representative of three independent experiments.
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6SI Table 1 Paullone SAR. Effects of substitution to the paullone scaffold (SI Fig. 5A) as
determined by Nanog activity. Bolded data represent modification to the paullone
carbon backbone.
Position Substitution
1 C = N > S
2 H > OH > OCH3 > short alkyl chain >>> bulky substituents (nottolerated)
2 C >> N (nitrogen abolishes activity)
3 H > OCH3 > OH
4 H >> OH > OCH3
4 C > N
5 H > CH3 > hydroxy-amidine > p/Cl-Bz >> bulky substituents
9 Br = I = CH3 > CF3 > OCH3 > Cl >>> bulky and (F,CN,OH,H,CO2H,NO2) not tolerated
11 C > N
12 N >> O
12 H > CH3 >>> bulky substituents (not tolerated)
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7SI Table 2 Tyrosine kinase panel. Data is represented as percent kinase inhibition (% i)
in the presence of 5 µM Kun 152. Kun152 increases the Nanog luciferase signal 2.4-
fold, relative to DMSO-treated controls.
Kinase % i
Abl 7
Abl (T315I) 12
Akt1 4
AMPK 10
AurB 15
AXL 11
BMX -8
BTK -7
CaMK2a 31
CDK2/cycA 19
CHK2 12
CK1a 5
cKit -2
c-RAF 6
CSK 3
DYRK1a 4
EGFR -2
EphA3 7
EphB3 2
Kinase % i
FAK2 7
FGFR3 1
Flt3 15
FMS/CSF1R 31
Fyn 5
GSK3b 52
IGF1R -12
IKKb 1
InsR -29
IRAK4 1
JAK2 -1
JNK2a2 5
KDR 14
Lck 8
Lyn 23
MAPK1 3
MAPK13 -7
MAPK14 -6
MAPKAPK2 7
Kinase %
i
MET 5
NEK2 7
p70S6K 4
PAK2 1
PDGFRa -6
PDK1 6
Pim2 3
PKA -1
PKCa -2
PLK1 6
RET 1
ROCK2 5
RSK1 3
SGK1 8
Src 11
Syk 1
TrkA 10
TTK 8
ZAP70 -14
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8SI Table 3. Kinase inhibition profile for the small molecule inhibitors used in this study.
Class indicates whether the small molecule is a CDK inhibitor (CDKi), GSK-3β inhibitor
(GSKi) or an inhibitor of both CDKs and GSK-3β (dual). Data is reported as the IC50 in
µM for in vitro kinase inhibition.  n/a, data not available.
Compound Class Cdk1
Cdk2/Cyclin
A
Cdk2/Cyclin
E Cdk5
GSK-
3β
Kenpaullone (11, 12) Dual
0.4
0.68 7.5 0.85 0.23
Flavopiridol (13) Dual 0.4 n/a n/a n/a 0.45
Aloisine (14) Dual 0.7 n/a n/a 1.5 0.92
Aloisine A (14) Dual 0.15 0.12 0.4 0.2 1.5
BIO (13, 15) Dual 0.32 0.3 n/a 3 0.005
Hymenialdisine (13,
16) Dual
0.02
2 0.07 0.04 0.028 0.01
Purvalanol A (17) CDKi 0.004 0.07 0.035 0.075 >10
Roscovatine (18) CDKi 0.65 0.7 0.7 0.2 n/a
NU6102 (19) CDKi 0.01 0.0054 n/a n/a n/a
AR-A014418 (13,
20) GSKi n/a >100 >100 >100 0.104
CHIR99021 (13, 21) GSKi 8.8 n/a n/a n/a 0.007
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9SI Table 4.  List of primers used for semi-quantitative RT-PCR.
Gene (NA #) Forward Primer Reverse Primer
Nanog
(NM_028016.2)
AGGGTCTGCTACTGAGATGCTCTG CAACCACTGGTTTTTCTGCCACCG
Nat1 (NM_008673.1) ATTCTTCGTTGTCAAGCCGCCAAAGTGGAG AGTTGTTTGCTGCGGAGTTGTCATCTCGTC
Cdc2 (NM_007659) GTCCGTCGTAACCTGTTGAG CATGTTAATTAAGTTATACGTAGG
Cdk2 (NM_183417) GGAGAACTTTCAAAAGGTGG CCGTGAGAGCAGAGGCATCCATG
Gsk-3β
(NM_019827.6)
CAGAGTCGCCAGACACTATAGTCGA GCCGGAAGACCTTTGTCCAA
Cdk5 (NM_007668.3) TCTGAAGCGTGTCAGGCTGG ACAAGCTGTGGGCCACATCA
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SI Table 5.  List of short hairpin (sh)RNA sequences used for knock-down analysis.
Gene 19mer Short Hairpin RNA
Sequences
GTTCTACAGGACAAGCGAT
GTGATTGGAAATGGATCAT
GTTGTATATGTATCAGCTG
GATGAGGTCTACCTTAACC
Glycogen Synthase Kinase-3β (GSK-3β)
GCATGAAAGTTAGCAGAGA
GGGCCCTATTCCCTGGAGA
GCCTGATTATAAGCCAAGT
GCAGCCCTGGCTCACCCTT
GCTGCTCCAGGGCCTGGCT
Cyclin Depdendent Kinase 2 (CDK2)
GGTGTACCCAGTACTGCCA
GGCTTCATGATGTCCTGCA
GCTGCTGAAAGGCCTGGGA
GACTATAAGCCCTACCCAACyclin Depdendent Kinase 5 (CDK5)
GTGGTCAGCCGGCTGCATC
GCACCCGTACTTTGATGAC
GGAGTGCCCAGTACTGCAA
GGGACCATATTTGCAGAAC
Cell division cycle 2 homolog A (CDC2A)
     Also known as CDK1
GAACACCTTTCCCAAGTGG
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